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Summary 
Epstein-Barr virus (EBV) infects an estimated 95% of the adult population and establishes a 
life-long persistent infection in B-Lymphocytes. While primary infection is usually without 
symptoms, latent infection with EBV is associated with Burkitt's Lymphoma (BL) and several 
other forms of B-cell malignancies that are a challenge for medicine. The evident association 
of Burkitt's lymphoma with Plasmodium falciparum infection suggests a role for co-infections 
in the etiology of BL, even though the exact mechanism is not known to date. Chronic 
infection with P. falciparum causes strong stimulation of innate immune pathways by 
triggering germ-line encoded pattern-recognition receptors such as Toll-like receptors 
(TLRs). Importantly, stimulation of TLR9 signaling has been shown to have a direct impact 
on EBV gene expression and reactivation, providing a possible connection between P. 
falciparum and malignancies arising from latently EBV-infected B-cells. 
In the work presented here, we used murine gamma-herpesvirus 68 (MHV-68) to investigate 
the impact of endosomal TLRs 7 and 9 on gamma-herpesvirus reactivation and establishment 
of latency. The use of MHV-68 allowed us to not only study endosomal TLR triggering in 
vitro, but also assess the consequences of repeated TLR stimulation in vivo. We found that 
stimulation of TLR7 and TLR9 suppresses lytic MHV-68 gene expression via activation of 
the cellular transcription factor NF κB, therefore maintaining the virus in the latent state. In 
immune competent hosts, the repeated administration of TLR7 ligand was found to augment 
the frequency of latently infected cells, indicating that constant stimulation of innate immune 
receptors promote MHV-68 latency. 
Our results demonstrate that a pathway of the innate immune system suppresses MHV-68 
lytic replication via activation of NF κB and favours the establishment of latent infection. 
This provides insight into a possible role for co-infections in the etiology of gamma-
herpesvirus-associated malignancies and will hopefully open up new avenues for 
understanding and preventing these cancers. 
Zusammenfassung 
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Zusammenfassung 
Das Epstein-Barr Virus (EBV) infiziert geschätzte 95% der erwachsenen Weltbevölkerung 
und etabliert eine lebenslang persistierende Infektion in B-Lymphozyten. Während die 
Primärinfektion üblicherweise ohne Symptome verläuft, ist latente EBV Infektion mit 
Burkitt's Lymphomen und anderen Formen von bösartigen B-Zell Tumoren assoziiert, die 
eine Herausforderung für die Medizin darstellen. Die erwiesene Assoziation von Burkitt's 
Lymphomen mit Plasmodium falciparum deutet darauf hin, dass Co-Infektionen bei der 
Entstehung von BL eine Rolle spielen, auch wenn der genaue Mechanismus bis heute 
unbekannt ist. Durch das Auslösen von Rezeptoren, die körperfremde Muster erkennen wie 
zum Beispiel Toll-like Rezeptoren (TLRs) verursacht chronischer Befall mit P. falciparum 
eine starke Stimulierung von Signalwegen des angeborenen Immunsystems. Es wurde 
gezeigt, dass die Stimulierung von TLR9 einen direkten Einfluss auf EBV Genexpression und 
Reaktivierung hat, was eine mögliche Verbindung zwischen P. falciparum und dem Auftreten 
von Tumoren aus EBV-infizierten B-Zellen darstellt. 
In der hier vorliegenden Arbeit haben wir einen murinen gamma-Herpesvirus (MHV-68) 
verwendet, um den Einfluss der endosomalen TLRs 7 und 9 auf gamma-Herpesvirus 
Reaktivierung und Etablierung der Latenz zu untersuchen. Die Verwendung von MHV-68 
erlaubt es, nicht nur den Effekt endosomaler TLR Signale in vitro zu studieren, sondern auch 
die Konsequenzen wiederholter TLR Stimulierung in vivo. Wir haben gezeigt, dass 
Stimulierung von TLR7 und 9 die Expression von lytischen MHV-68 Genen durch die 
Aktivierung des zellulären Transkriptionsfaktors NF κB unterdrückt und das Virus dadurch 
im Zustand der Latenz hält. Im immunkompetenten Wirt führte die wiederholte Zugabe von 
TLR7 Ligand zu einer erhöhten Frequenz an latent infizierten Zellen, was darauf hindeutet, 
dass konstante Stimulierung von Rezeptoren des angeborenen Immunsystems latente 
Infektion von MHV-68 fördert. 
Unsere Resultate zeigen, dass ein Signalweg des angeborenen Immunsystems die Fähigkeit 
hat, die lytische Replikation von MHV-68 durch Aktivierung von NF κB zu unterdrücken, 
was die Etablierung einer latenten Infektion begünstigt. Diese Erkenntnis bietet einen 
Anhaltspunkt für die mögliche Rolle von Co-Infektionen bei der Entstehung von gamma-
Herpesvirus-assoziierten Tumoren und wird hoffentlich neue Wege aufzeigen diese Tumore 
zu verstehen und zu verhindern. 
Introduction 
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Introduction 
 
Epstein-Barr Virus and associated lymphoma 
Epstein-Barr virus (EBV) is a B-lymphotropic virus belonging to the subgroup of gamma-
herpesviruses. The virus is very widespread in the adult population with an estimated 95% of 
the people being seropositive. Despite the infection being generally without symptoms, EBV 
poses a great challenge for modern medicine due to the association of latent EBV infection 
with a range of malignant lymphomas in human patients.  
Primary infection with EBV generally occurs during infancy and is without symptoms 
in the vast majority of cases. Characteristically for all herpesviruses, EBV establishes a latent 
infection in the host with intermittent periods of active replication leading to the production of 
viral progeny necessary for transmission. Co-evolution of virus and host has established an 
intricate equilibrium where the virus persists in the host at low levels of infection without 
being cleared by the immune system and without apparent harm to the host.  
EBV was the first human gamma-herpesvirus detected and was originally described in 
1964 by Anthony Epstein, who identified viral particles in samples of Burkitt's Lymphoma 
from Uganda [1]. EBV was the first virus to be identified as a potential tumorigenic agent and 
EBV infection was subsequently found to be associated with other B-cell malignancies such 
as Hodgkin's disease [2] or post-transplant lymphoproliferative disorders [3]. EBV infection 
is also associated with non-B-cell tumors such as nasopharyngeal carcinoma [4] where EBV 
latency genes are found in the majority of cases [5] and is also found in 10% of all gastric 
carcinomas [6]. The tumorigenicity of EBV is confirmed experimentally by the fact that 
infection with EBV is sufficient to growth-transform human B-lymphocytes in vitro [7]. A 
second member of the human gamma-herpesvirus family was detected in 1994 in Kaposi's 
sarcoma tissue obtained from patients with acquired immunodeficieny syndrome (AIDS) and 
was termed Kaposi's sarcoma-associated Herpesvirus (KSHV) [8]. The same viral entity was 
found to be associated with lymphoproliferative disorders such as Multicentric Castleman's 
Disease [9] and primary effusion lymphoma (PEL) [10], indicating that tumorigenicity is not 
a trait exclusive to EBV but might be a feature common to all gamma-herpesviruses. 
EBV-associated lymphoma are relatively rare considering a majority of adults is 
latently infected. It has therefore become a critical challenge to identify the mechanisms of 
gamma-herpesvirus-associated lymphomagenesis and the physiological circumstances that 
predispose an individual to EBV-associated malignancies. Some of these malignancies occur 
in patients where the immune system is weakened due to immunosuppressive treatment after 
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organ transplantation or advanced stages of acquired immunodeficiency syndrome (AIDS) 
caused by infection with human immunodeficiency virus (HIV). These incidents of EBV-
positive lymphoma are likely explained by the deteriorating immune control of latently 
infected B-cells through cytotoxic immune cells and underscore the importance of constant 
immune supervision to balance asymptomatic latent infection. 
However, EBV-positive lymphoma also occur in immunocompetent patients, the 
prime example being endemic Burkitt's Lymphoma (eBL), the tumour entity in which EBV 
was first identified. Notably, these tumours occur almost exclusively in areas where the 
causative agent of malaria, Plasmodium falciparum is holoendemic [11,12], demonstrating a 
role for co-infections in the ontology of EBV-associated lymphoma in immunocompetent 
patients that is unclear so far. 
Unfortunately, the study of EBV infection and associated lymphomagenesis in the 
context of an intact immune system is hampered by the strict species specificity of EBV, 
therefore, a robust animal model is vital to understand the interplay between virus and host 
immunity. Murine gamma-herpesvirus 68 (MHV-68) is widely used as a model to investigate 
gamma-herpesvirus infection in vivo as it readily infects common strains of laboratory mice. 
MHV-68, which was originally isolated from free-living wood mice, is genetically closely 
related to EBV and shares important features of its biology, including types of infection 
(productive replication and latency), primary site of latent infection (B-cells) and associated 
diseases (lymphoproliferative malignancies). By studying MHV-68 infection in mice, we 
have gained a lot of insight about gamma-herpesvirus biology in general, from the course of 
initial infection and the establishment of latency to host immune response and viral immune 
evasion. 
 
 
MHV-68: a model for gamma-herpesvirus infection in vivo 
My work described in this thesis focuses heavily on using MHV-68 infection of laboratory 
mice to study gamma-herpesvirus biology both in vitro and in vivo. In order to evaluate the 
results of my study and put it in the proper context, I have written a review that summarizes 
the knowledge gained about gamma-herpesvirus infection in vivo using this system and that is 
currently in preparation for submission (see below). It serves to illustrate the possibilities, but 
also the limitations of the system with respect to investigating EBV-associated 
lymphomagenesis, as is known up to now. 
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Origin of MHV-68 and natural host reservoir 
How MHV-68 was first isolated and introduced into experimental animals is rather intriguing 
and important for the characteristics exhibited during infection. Five different strains of a 
herpesvirus were isolated from two different free-living small rodent species (Apodemus 
flavicollis and Clethrionomys glareolus) during field studies in Slovakia in 1980 [13]. It was 
concluded that these viruses were probably geographically widespread throughout mouse and 
vole subfamilies. Noteworthy, all five strains were able to replicate in fibroblast cell cultures 
from various animal species (birds, rodents, pigs, monkey) and man, which is interesting 
since gamma-herpesviruses normally have a very narrow range of host specificity. Based on 
the growth characteristics and cytopathic changes typical for members of the herpesvirus 
family all five murid herpesvirus 4 isolates were originally classified as Alphaherpesvirinae 
[14].  
Subsequent field studies in the UK found that 13-24% of wood mice (Apodemus 
sylvaticus) have serum antibodies reactive to MuHV-4 contrasting 3% of bank voles 
(Clethrionomys glareolus) and confirmed the presence of MuHV-4 DNA in the lungs and 
spleens of infected animals. This suggests that wood mice are indeed the natural host rather 
than voles [15,16]. In free-living animals of the species used for laboratory work (Mus 
musculus), MuHV-4 was very rarely detected [17], indicating that Mus musculus is only an 
accidental host and prompting the question whether an infection of laboratory mice reflects 
the natural course of infection. Indeed, the course and characteristics of MHV-68 infection in 
wood mice differ from those in the commonly used laboratory experimental mouse strain 
BALB/c in terms of titers during acute infection in the lungs as well as some features of viral 
immune evasion. Nevertheless, the overall characteristics of gamma-herpesvirus infection 
seem to be present in laboratory mice [18,19]. Therefore, infection of mice with MuHV-4 is a 
promising model system to study gamma-herpesvirus biology under controlled laboratory 
conditions and the presence of an intact immune system enables us to investigate the role of 
immune stimulation. Additionally, the availability of genetically engineered mouse strains 
provides a powerful tool to study the interaction of gamma-herpesviruses with specific parts 
of the host immune system in order to learn how chronic infection is controlled in vivo.  
 
Classification and genetic relation to human herpesviruses 
Sequence analysis of restriction fragments revealed that MHV-68 is more closely related to 
gamma-herpesviruses than to the Alphaherpesvirinae as originally classified based on in vitro 
culture characterization [20]. Further molecular studies showed that the MHV-68 genome 
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consists of a singular stretch of 118kb unique DNA sequence flanked by a variable number of 
terminal repeats. This genomic structuring is strikingly similar to that of a subgroup of 
gamma-herpesviruses termed gamma-2 or Rhadinovirus, comprising herpesviruses from New 
World monkeys such as herpesvirus saimiri (HVS) and herpesvirus ateles (HVA) but also 
human pathogenic KSHV [21]. The other subgroup of gamma-herpesviruses termed gamma-1 
or Lymphocryptovirus, comprise human pathogenic EBV and several simian herpesviruses 
detected in Old World non-human primates (Fig. 1). In contrast to the gamma-2 
herpesviruses, they have a coding region divided into two segments (small and large unique 
region) divided by internal repeated regions and flanked by terminal repeats [22]. Based on 
these characteristics, MHV-68 was classified as belonging to the order Herpesvirales, family 
Herpesviridae, subfamily Gammaherpesvirinae, genus Rhadinovirus and species Murid 
Herpesvirus 4 [23]. Phylogenetic analysis suggests that MuHV-4 and primate rhadinoviruses 
diverged about 60 million years ago [24]. 
 
Figure 1. Phylogenetic tree for the Gammaherpesvirinae showing the two distinct subgroups, 
Lymphocryptovirus (gamma-1-herpesvirus) and Rhadinovirus (gamma-2-herpesvirus) (adapted from DJ 
McGeoch et al. [25]). Species mentioned in the text are shown in bold. 
 
Complete sequencing of the MHV-68 genome predicted at least 80 open reading 
frames (ORFs), 63 of which are co-linear and homologous to rhadinoviruses HVS and KSHV 
and many of which are also present in the EBV genome [26]. The considerable amount of 
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conservation is a strong indication of common mechanisms for host colonization and 
regulation of the viral life cycle, which is a prerequisite to use MHV-68 infection as a model 
system for gamma-herpesviruses. However, interspersed in between these conserved blocks 
of genes, which seem to be common to all gamma-herpesviruses, each virus contains a 
number of unique genes, which may reflect host-species-specific adaptations or constraints. 
MHV-68 contains 14 ORFs, which have no apparent homologs in HVS, KSHV, or EBV and 
seem to be specific for this particular virus. Notably, none of the EBV latency-associated 
genes that have been shown to be essential for transformation of B-cells in vitro (LMP1, 
EBNAs) appear to have any homologs in the other gamma-herpesviruses. This in turn means 
that while MHV-68 and EBV share large homology in their genomes and therefore have 
probably many common features, there are also differences affecting the maintenance of 
latent infection and possibly the oncogenic potential of the virus. 
 
MHV-68 infection in vitro 
As mentioned above, MHV-68 readily infects fibroblast cell lines of various origin [14]. In 
these cells, MHV-68 replicates with concurrent expression of most viral genes, leading to 
cytopathic effects (CPE) (Fig. 2) and accumulation of high titers of infectious viral particles 
in the supernatant, similar to human rhadinovirus KSHV, that causes CPE and replicates in 
human embryonal-kidney epithelial cells 293 [27]. In contrast, the infection of epithelial cells 
in vitro by cell free EBV is very inefficient and seems to require the presence of infected B-
cells in a transfer infection assay [28]. 
Figure 2. Lytic infection of mouse fibroblast cell line NIH3T12 with MHV-68 in vitro. NIH3T12 cells were 
grown to a monolayer and then infected with MHV-68 at a multiplicity of infection of 0.1. A) At the day of 
infection, fibroblasts are forming a tight monolayer. B) 3 days post infection, foci of detached cells have 
appeared, forming holes in the monolayer and indicating cytopathic effect through lytic viral replication. C) 7 
days post infection, initial infection has spread and a majority of fibroblasts have detached from the plate. 
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In vivo, B-lymphocytes are thought to be the major reservoir of gamma-herpesvirus latency, 
therefore considerable effort has been put into studying infection of B-lymphocytes in vitro. 
Indeed, it was found that MHV-68 persistently infects mouse myeloma cells NSO (B-cells) 
but not mouse thymoma cells BW5147 (T-cells) [29]. Infection of primary murine B-
lymphocytes in vitro leads to activation, proliferation and prolonged survival of these cells. 
However, there is no evidence of productive MHV-68 replication and the viral genome is 
found predominantly in a linear form instead of the circularized genome typical for viral 
latency [30]. This suggests that MHV-68 enters primary B-lymphocytes in vitro and that the 
viral genome is successfully uncoated, but persistent infection or growth-transformation is not 
achieved. Again, this is in sharp contrast with EBV, where infection of primary B-
lymphocytes in vitro is very efficient and growth-transformation leads to the outgrowth of 
persistently infected lymphoblastoid cell lines [7]. It is likely that the contrasting results of in 
vitro infection reflect the differences in latency genes being expressed in the host cell and 
highlights the importance of the EBV latency genes for efficient transformation. 
 
Course of infection in immunocompetent mice 
Even though field studies suggest that laboratory mice (Mus musculus) are not the natural 
host for MHV-68 (see above), the virus exhibits a course of infection typical for gamma-
herpesviruses in immunocompetent inbred mouse strains by establishing a persistent life-long 
infection without apparent signs of disease. Nonetheless, one of the unresolved questions of 
the MHV-68 mouse model is how the virus manages to colonize its host. Despite efforts to 
study transmission from infected to naive mice, the route of initial infection is still somewhat 
unclear. There have been reports of vertical transmission from chronically infected females to 
newborn pups [31] either via transplacental transmission or via shedding of infectious 
particles in breast milk similar to the beta-herpesvirus murine Cytomegalovirus (mCMV) [32] 
or the human virus KSHV [33]. Indeed, the gastrointestinal tract seems to fulfill the 
requirements of a portal of entry, since oral administration or gastric instillation of MHV-68 
can lead to the establishment of latent infection in the spleen [34]. Any attempts to study 
horizontal transmission within a population have been largely unsuccessful. Therefore, it is 
unclear how MHV-68 spreads under natural circumstances. A recent study reports MHV-68 
shedding by genital excretion and transmission from infected females to naive males via 
sexual contact [35], a route that is also used by Herpes simplex virus (HSV) type 2 [36]. 
Finally, the detection of MHV-68 DNA in ticks (Ixodes ricinus) by polymerase chain reaction 
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raises the possibility of a role for arthropode vectors in transmission of MHV-68 in nature 
[37]. 
Human gamma-herpesviruses are mainly transmitted via airborne infection and 
colonize the new host via airway epithelia, and shedding of virus into saliva of infectious 
patients have been shown for both EBV and KSHV [38-40]. In an attempt to model natural 
gamma-herpesvirus infection, the most common technique of experimental infection is 
therefore intranasal inoculation to allow access to the epithelium of the upper respiratory tract. 
The respiratory tract likely represents a natural route of infection, but experimental i.n. 
inoculaton of MHV-68 is not without pitfalls. Although i.n. inoculation of MHV-68 has to be 
done under general anesthesia, this does not ensure an equal infectious dose due to unknown 
amounts of inoculum being swallowed. As an alternative, intra-peritoneal (i.p.) injection of 
MHV-68 allows direct seeding to the major reservoir of latent infection, i.e. the spleen [41]. 
This results in robust latent infection of splenocytes and establishes long-term infection in 
peritoneal macrophages [42]. Different infection techniques may present advantages in 
specific experimental settings, nevertheless, intranasal inoculation is most widely used today. 
After intranasal inoculation, replicating MHV-68 can be detected in the lungs [43]. 
The main site of this acute replication phase following primary infection seems to be alveolar 
epithelium, where MHV-68 replicates to high titers during the first three days. The acute 
infection phase is terminated by a robust immune response in immunocompetent mice as 
macrophages and mononuclear cells, predominantly CD8+ T-cells, infiltrate the lungs and 
infectious virus is largely cleared 7-10 days post inoculation. Acute viral replication in the 
respiratory tract generally takes place without clinical symptoms but may lead to severe 
disease that can even be fatal in some cases [43]. 
In a second phase, MHV-68 eventually gains entry to the lymphoid compartment, most likely 
by infecting B-lymphocytes in the local mediastinal lymph nodes (MLN). Evidence suggests 
that dendritic cells (DCs) play an important role in delivering virus to the MLN. The use of a 
recombinant marker virus revealed that a significant fraction of virus found in B-cells bore 
genetic marks from an earlier passage in dendritic cells and a virus attenuated for replication 
in DCs showed severe impairment in B-cell colonization [44]. This suggests that MHV-68 
uses DCs to bridge the gap from initial replication in alveolar epithelium to reaching the MLN 
and thus gaining access to the lymphoid compartment. From the MLN, MHV-68 spreads to 
the spleen and other lymphoid tissues, presumably via infected circulating B-lymphocytes. 
This is suggested by the observation that B-cell deficient mice exhibit strong impairment of 
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latency establishment in the spleen following intranasal inoculation despite normal titers in 
the lung [45]. 
By the second week of infection, a rapid expansion of latently infected cells is 
observed in the spleen [46], which is thought to be the major latency reservoir during 
persistent infection. Latency in the spleen is initially established in three different cell types, 
B-lymphocytes, macrophages and DCs [47]. While B-cells represent the majority of latently 
infected cells, they are not essential for the establishment of latency as other cell types can 
sustain persistent infection in B-cell deficient animals [41]. Around two weeks post infection, 
the frequency of infected splenocytes reaches a peak and the majority of infected cells have 
the phenotype of activated germinal center B-cells [48]. 
Concomitantly with the establishment of latency in the spleen, a marked splenomegaly 
develops in infected mice in the first 2-3 weeks post infection (Fig. 3). 
 
Figure 3. Splenomegaly in C57BL/6 mice after MHV-68 infection. A) Spleen weight relative to total body 
weight transiently increases after infection (d pi = days post infection). B) Enlarged spleen from a mouse on day 
18 post infection (left) in comparison to a spleen from an uninfected mouse (right). 
 
MHV-68-induced splenomegaly is caused by an increase in the numbers of B-cells, 
CD4+ and CD8+ T-cells, but most pronounced is the increase in CD8+ T-cells [49]. The 
phenomenon is dependent on the presence of B-cells as well as CD4+ T-cells, depletion of 
which has been shown to result in absence of splenomegaly [45]. While splenomegaly 
generally resolves around 1 month post infection, a pronounced lymphocytosis prevails in the 
peripheral blood of infected mice for at least another month [50], which bears striking 
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resemblance to the Infectious Mononucleosis (IM) syndrome associated with primary EBV 
infection [51]. Similar to IM patients, where mono- or oligoclonal populations of CD8+ T-
cells make up the major part of lymphocytosis in the blood [52], in MHV-68 infected mice, 
the numbers of activated CD8+ T-cells in the periphery is elevated up to 4-fold. Interestingly, 
these T-cells show a significant skewing in T-cell receptor usage with up to 75% of CD8+ T-
cells expressing Vβ4 chain in their αβTCR [50]. The Vβ4-specific T-cell stimulatory activity 
does not seem to depend on classical MHC class I or II antigen presentation [53] and displays 
some features reminiscent of a viral superantigen [54]. Indeed, the gene product of MHV-68-
specific ORF M1 was shown to be a secreted protein that has the ability to stimulate Vβ4+ 
CD8+ T-cells and act as immunoregulatory factor with superantigen-like properties [55]. 
As infection progresses, the pool of latently infected splenocytes decreases 
significantly, from about 1 in 100 cells to 1 in 20'000 cells by 3 months post infection. During 
this period, the fraction of non-B-cells and naive B-cells contributing to the latently infected 
cell pool diminishes greatly. At late time points post infection, latency is maintained at steady 
levels, presumably balanced by continuous immune surveillance and MHV-68 is found 
preferentially in surface IgD- splenic B-lymphocytes that have the phenotype of long-lived 
memory B-cells [56]. The establishment of long-term latency by accessing the memory B-cell 
pool is a feature MHV-68 shares with the human virus EBV, which is found in the peripheral 
blood of healthy carriers exclusively in resting memory B-cells [57], and likely represents a 
conserved strategy of gamma-herpesviruses.  
The maintenance of a steady level of infected cells indicates equilibrium between 
latency, reactivation and immune control that ensures life-long infection without adverse 
effects for the host. Notably, dose and route of inoculation do not influence the level of 
latently infected cells, as infections with a range of 6 logs of infectious MHV-68 particles 
injected intraperitoneally or a range of 5 logs of infectious particles administered intranasally 
resulted in comparable levels of infected splenocytes during long-term latency [58]. These 
results argue that a maximal level of latency is established in the spleen and that there are 
homeostatic mechanisms in place to ensure long-term infection in immunocompetent hosts. 
 
Immune response to MHV-68 
One of the biggest draws of the MHV-68 mouse model is the ability to study immunity-
related host-pathogen interactions in vivo. The availability of a wide array of genetically 
engineered mouse strains that lack specific components of the immune system allows 
researchers to identify immune responses against different stages of gamma-herpesvirus 
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infection. Gamma-herpesviruses are difficult targets for the immune system since they are 
exquisitely adapted by co-evolution to establish life-long infections and avoid clearance in an 
immunocompetent host. As discussed above, infection with MHV-68 is characterized by 
distinct phases from acute infection in the lung, latency establishment in lymphoid organs 
with concomitant expansion of latently infected cells, subsequent contraction of the pool of 
infected cells and onset of long-term latency in memory B-cells. Consequently, different 
immune effector mechanisms are involved in controlling the distinct phases of MHV-68 
infection, and immune responses that are effective against any particular phase of infection 
might be non-effective against another. Additionally, MHV-68 has evolved an array of 
measures to evade the immune responses and there is evidence that the virus even diverts 
cellular signaling pathways involved in immunity to drive certain aspects of its life cycle 
(discussed below). 
 
Innate immunity 
Interferon 
In mammals, interferons (IFNs) are cytokines that constitute an important first line of defense 
against viral infection, hindering replication and therefore viral spread until adaptive 
immunity has had time to be mounted [59].  
Mice deficient for the type I IFN receptor (ifnr-/-) undergo an aggressive infection of 
the lung upon i.n. inoculation, with virus titers 100-1’000 fold higher than those in congenic 
wild-type mice [60]. Consequently, up to 90% of these mice succumb to high doses of virus 
due to interstitial pneumonia with focal hemorrhage and necrosis and still 30% of mice do not 
survive low-dose infection, indicating that IFN I signaling plays an important role in limiting 
initial acute replication. ifnr-/- mice also show 10-fold higher numbers of latently infected cells 
in the spleen initially, but 3 weeks after infection, frequencies of latently infected splenocytes 
are similar in ifnr-/- and wt mice, indicating that type I IFNs are dispensable for controlling 
latency. Type I IFNs might still play role in regulating viral latency, since infected 
splenocytes lacking type I IFN receptor were found to reactivate with higher efficiency ex 
vivo than splenocytes from wt mice [61]. How this observation translates to the situation in 
vivo is not entirely clear. 
In contrast to type I IFNs, type II IFN does not appear to be required for clearance of 
acute infection in the lung. Mice deficient for IFN-gamma receptor (ifngr-/-) showed no 
difference in viral titers or clearance of MHV-68 from the lung [62,63]. Despite the 
apparently unimpaired control of lytic infection, ifngr-/- mice succumb later during infection to 
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severe incidents of inflammatory pathologies such as large vessel arteritis [64] or multi-organ 
fibrosis [65]. At 5-12 months post infection, ifngr-/- mice can develop inflammatory lesions in 
the lungs that progress to lymphoid hyperplasia or pulmonary lymphoma [66]. These 
observations indicate that mice deficient in type II IFN are impaired in controlling chronic 
infection rather than the acute phase in the lungs. Indeed, IFN-gamma was shown to suppress 
reactivation of MHV-68 from latently infected cells [67], suggesting that the inflammatory 
pathologies observed in ifngr-/- mice might be due to persistent reactivation and replication of 
virus in lung tissue. An important caveat when discussing the role of IFN-gamma in the host 
response to MHV-68 is the observation that dependence on type II IFN signaling for 
successful clearance of acute infection from the lung is dependent on the mouse strain. While 
ifngr-/- mice on a C57BL/6 genetic background are able to control pulmonary infection as 
efficiently as wild-type controls, ifngr-/- on a BALB/c background are impaired in clearance of 
MHV-68 from the lung as evidenced by higher viral titers and increased mortality [68]. 
 
Toll-like receptor signaling 
The family of Toll-like receptors (TLRs) is an integral part of innate immunity whose 
function is to recognize non-host structures and molecular patterns, initiate an inflammatory 
response through expression of cytokines, and help to shape the adaptive immune response 
[69]. Among the twelve TLRs described in mice so far [70], TLR7 and TLR9 recognize 
foreign nucleic acid and have been shown to be important in the recognition of viral 
infections. Upon binding of their respective ligand, TLR7 and TLR9 signal via a shared 
pathway through the adaptor molecule myeloid differentiation primary response protein 88 
(MyD88) that culminates in the activation of the transcription factor nuclear factor κB 
(NFκB), which induces expression of cytokines, adhesion molecules and other cellular 
mediators that serve to activate and prime the adaptive immune response. 
Mice that are deficient for the TLR-adaptor protein MyD88 and therefore lack TLR7- 
and TLR9-mediated signaling clear acute infection in the lungs without notable differences to 
the wt controls, indicating that TLR7 or TLR9 signaling is not crucial for clearance of MHV-
68 from the lungs. Latency establishment in the spleen was significantly disturbed though, 
resulting in a 10-fold decrease in the frequency of infected cells. Infection of wt x myd88-/- 
bone-marrow chimeric mice confirmed that MHV-68 efficiently established latency in 
myd88+/+ B-cells but not in myd88-/- B-cells [71]. The observed impairment of MHV-68 to 
establish latency in cells without functional MyD88 argues for an important role of TLR7 and 
TLR9 signaling in latent infection and illustrates the hijacking of a cellular immune pathway 
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by MHV-68 for its own benefit. This hypothesis is further substantiated by the observation 
that a recombinant strain of MHV-68 that suppresses NFκB activation in infected cells by 
constantly expressing the inhibitory molecule IκBα, had a similar phenotype in vivo with 
substantially decreased numbers of latently infected cells in the spleen [72]. Besides 
supporting latent infection, NFκB activation also exhibits protective properties however, since 
mice deficient for NFκB subunit p50 have 10- to 100-fold higher viral titers in the lungs early 
after i.n. inoculation. Despite this apparent deficiency in limiting acute replication, p50-/- mice 
are nonetheless able to clear acute infection [73]. 
Taken together, published data suggest that gamma-herpesviruses have evolved 
mechanisms to usurp important signaling pathways of the innate immune system to ensure 
long-term persistence in infected cells and possibly also to regulate viral gene expression and 
thus their life-cycle. 
 
Natural killer (NK) cells 
The cellular component of the innate immune system consists of natural killer (NK) cells that 
have the ability to induce apoptosis in cells displaying altered expression of surface molecules 
such as virus-infected cells or cancer cells. NK cells have been shown to be important in the 
immune response to alpha-herpesvirus HSV-1 [74] and beta-herpesvirus cytomegalovirus 
[75]. In contrast, NK-cell depletion or genetic deficiency of NK cells did not alter the course 
of lytic or latent MHV-68 infection in mice [76]. NK cell populations in the mouse are found 
to be elevated shortly after MHV-68 infection and these cells show markers of activation and 
prove capable of cytotoxic killing of target cells in vitro upon explant, however, depletion of 
NK cells does not impact the viral titers in the lungs [77]. Thus, the contribution of NK cells 
to the control of MHV-68 seems negligible. This contrasts the observations related to EBV-
associated B lymphocyte transformation [78] (Lünemann A et al. JI 2013, in press). 
 
Adaptive immunity 
CD8+ T-cells 
CD8+ cytotoxic lymphocytes (CTLs) play a major role in controlling primary lytic MHV-68 
infection. While viral titers in the lungs normally peak around 3 days post infection and 
infectious virus is cleared from the lungs approximately 1 week post infection, depletion of 
CD8+ T-cells not only results in higher peak titers but also failure to clear infectious virus and 
thus increased pathology [79]. Similarly, β2-microglobulin-/- mice that lack CD8+ T-cells were 
found to be unable to clear infectious virus from the spleen after intraperitoneal inoculation 
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[41], confirming the importance of CD8+ T-cells in eliminating acute replication. In turn, mice 
that were primed with a recombinant vaccinia virus expressing the most prominent CD8+ T-
cell epitope of MHV-68 lytic cycle protein p56 have a strongly reduced productive infection 
in the lungs and initially delayed kinetics in the establishment of latency in the spleen. 
Eventually, latent infection in the spleen reaches levels of wt mice though, indicating that a 
primed CD8+ T-cell response is very efficient at terminating acute replication but is not 
sufficient to prevent latency [80]. 
In addition to the crucial role in the control of acute replication in both the lungs and 
spleen, CD8+ T-cells apparently also regulate latency at later time points, as cd8-/- mice were 
found to have about 6-fold higher frequencies of latently infected splenocytes [81]. The CD8+ 
T-cell response developing after inoculation of MHV-68 is directed against a broad repertoire 
of epitopes, identified from early and late lytic gene products [82]. Interestingly, the CD8+ T-
cell response seems to occur in two distinct phases that are dominated by CTL specific for 
two different gene products, ORF6 (p56) and ORF61 (p79). CD8+ T-cells specific for p56 
epitope dominate the early phase of infection during the peak of lytic replication in the lung 
but decline rapidly afterwards while responses against p79 emerge slower, peaking during 
latency establishment but are sustained longer, especially in the spleen [83]. The difference in 
kinetics between the two populations, together with the observation that p56-specific effector 
cells efficiently lysed virus-infected fibroblasts in vitro while p79-specific cells were less 
effective, suggest that the CD8+ T-cell response is mounted in two waves, one targeting 
replication in epithelium and another one targeting replication in B-cells during latency 
establishment. 
Notably, the CD8+ Vβ4+ T-cell population dominating during the infectious 
mononucleosis-like syndrome does not show specificity for any viral epitope tested so far and 
emerges later than the specific CD8+ T-cell population. A contribution of these cells to the 
immune response against MHV-68 therefore seems unlikely. Rather, the expansion of CD8+ 
Vβ4+ cells through a MHC class I-independent mechanism like a viral superantigen as has 
been speculated (see above), potentially serves to divert the immune system long enough to 
successfully establish long-term latency. 
CD8+ T-cells also play a role in controlling latent infection, but the viral epitopes 
involved in recognition of latently infected cells are not very well known so far. The only 
latency associated viral gene product shown to elicit specific CD8+ T-cell populations is M2 
[84]. M2 has no known homologues in other gamma-herpesviruses and is only transiently 
expressed during establishment of latency 1-3 weeks after i.n. inoculation. A population of 
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CD8+ T-cells specific for M2 was observed 2-3 weeks post infection, coincident with the 
decline in numbers of latently infected cells in the spleen. Consistent with the idea of this 
subset of CD8+ T-cells being instrumental in controlling the number of latently infected cells, 
adoptive transfer of an M2-specific T-cell line led to 30-80-fold reduction of infected 
splenocytes at day 14 post infection without apparent differences in lung viral titers. 
Vaccination with the M2 epitope resulted in a transient reduction of latently infected 
splenocytes but this did not translate into reduced long-term latency, indicating that infected 
splenocytes might only be susceptible to CD8+ T-cell attack in a limited time window during 
latency establishment but not during long-term latency [85]. 
Cytotoxicity mediated by specific CD8+ T-cells appears to be one of the most 
important immune responses to MHV-68 infection. Cytotoxic lymphocytes seem to be rather 
successful in fighting productively replicating virus both during early infection in the lung as 
well as during latency establishment in the lymphoid compartment. However, CD8+ T-cell 
responses are evidently unable to efficiently eliminate latent virus and CD8+ T-cell evasion is 
likely a driving force behind the evolution of gamma-herpesvirus latency with minimal viral 
gene expression. 
 
CD4+ T-cells 
The role of CD4+ T-cells is much less understood than of CD8+ T-cells. Recent studies 
underscore an important contribution of CD4+ T-cells to controlling gamma-herpesviruses 
and indeed, CD4+ T-cells specific for MHV-68 are detected early after infection and appear to 
retain an activated phenotype for at least 1 year [86]. 
Antibody-mediated depletion of CD4+ T-cells causes a slight delay in peak viral titers 
in the lungs after i.n. inoculation, but the mice are still able to clear acute infection, albeit with 
slower kinetics [79]. Interestingly, the proliferation of splenocytes at the onset of latency 
leading to the characteristic splenomegaly and latency amplification seen in 
immunocompetent mice is absent in CD4-depleted mice. Consequently, CD4-depleted mice 
show lower frequencies of infected cells in an infectious center assay compared to controls. 
Similar results were obtained after i.p. infection of CD4-depleted mice, splenomegaly was 
absent and the number of infectious centers dropped five-fold. However, from day 30 post 
infection onwards, the frequencies of infected cells in depleted and non-depleted mice were 
similar [49]. These experiments provide evidence that CD4+ T-cells are not necessary for 
MHV-68 clearance in the lungs but instrumental in driving lymphoproliferation in the spleen 
leading to splenomegaly and infectious mononucleosis-like syndrome. They might actually 
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have a beneficial function for MHV-68 during latency establishment in the first 2-3 weeks 
post infection by increasing the number of infected cells. Nevertheless, MHV-68 was able to 
establish long-term latency at a similar level with or without splenomegaly, so the initial 
expansion of the latent reservoir does not appear to be vital for long-term infection. While the 
CD4+ subset of T-cells has no influence on long-term latency, it clearly plays a role in the 
control of acute infection as evidenced by the fact that depletion of either CD4+ or CD8+ cells 
leads to a slight delay in clearance but not complete failure, while double depletion of CD4+ 
and CD8+ cells results in loss of control over acute infection and death [87]. 
The question arises whether CD4+ T-cells have direct effector function or they 
contribute to control of MHV-68 infection by providing help to other effector mechanisms 
either directly or through cytokine expression. The data collected up to date indicate that it is 
probably a combination of both. There is evidence for a role of cognate CD4+ T-cell help in 
maintaining long-term control of MHV-68 reactivation by CD8+ T-cells, since in mice 
deficient in MHC class II (mhcII-/-), progressively rising titers of infectious virus are found in 
the respiratory tract that are ultimately fatal [88]. 
An intrinsic, helper-independent role of CD4+ T-cells is suggested by the finding that 
ovalbumin-specific CD4+ T-cells are able to limit replication of a recombinant, OVA-
expressing MHV-68 strain and prolong survival of rag-/- mice in the absence of both CD8+ T-
cells as well as B-cells [89]. More recent studies documented direct effector functions of 
CD4+ T-cells against MHV-68. Purified CD4+ T-cells isolated from persistently infected mice 
have been shown to be able to directly recognize and kill MHV-68 loaded cells in an in vitro 
cytotoxicity assay in a MHC-dependent fashion. Additionally, specific killing of MHV-68 
loaded cells was observed in an in vivo cytotoxicity assay in persistently infected mice, which 
was abrogated upon depletion of CD4, indicating the existence of MHV-68-specific lysis 
mediated by CD4+ T-cells [90]. The dual role of CD4+ T-cells as a cytolytic effector and as a 
helper is further consolidated by the identification of two distinct CD4+ T-cell populations 
emerging in MHV-68 infected mice. One of the populations consists of steady state IFNg 
producers that are independent of antigenic restimulation in vitro, in contrast to virus-specific 
CD8+ T-cells that require antigenic stimulation for IFNg production. A second population 
stained positive for the surrogate marker of cytolytic T-cells, CD107, but not for intracellular 
IFNg, indicating that separate populations of CD4+ T-cells mediate cytolytic activity and 
cytokine production [91]. 
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Antibody response 
As discussed above, the cellular components of the adaptive immune response play important 
roles in fighting MHV-68 infection, especially in controlling initial acute infection. The 
antibody response is likely too slow to develop to substantially contribute to these early 
events. Significant virus-specific IgG titers appear only after day 10 post infection, at a time 
when acute infection in the lungs has already been resolved, and these titers continue to 
increase progressively until day 70 after infection [92]. Total IgG levels in the serum strongly 
increase from day 10 after infection, most likely due to the activation and proliferation of 
splenic B-cells during splenomegaly, but the fraction of IgG specific for MHV-68 is small. 
Loss-of-function studies to investigate the importance of a functional antibody immune 
response are somewhat limited since B-cells are the major target for latent infection. While 
MHV-68 manages to establish latent infection in B-cell-deficient mice, it is unclear how 
representative this kind of long-term infection is. Nevertheless, adoptive transfer of 
polyclonal antibody serum against MHV-68 can reduce the frequency of infected splenocytes 
in B-cell-deficient mice, indicating that antibodies might play a role in controlling latent 
infection, at least in non-B-cells [93]. The efficacy of antibody-related immunity in 
immunocompetent hosts is questionable, however, since MHV-68 is able to successfully 
establish latency despite high titers of virus-specific antibodies at later times of infection. 
Notably, while immune sera successfully blocked MHV-68 infection of fibroblasts, infection 
of Fc receptor-positive macrophages and dendritic cells was increased by neutralizing 
antibodies, arguing that Fc receptor-mediated uptake might present an alternative route of 
infection in susceptible cell types [94]. 
 
Immune evasion by MHV-68 
Gamma-herpesviruses have evolved a life cycle that relies on long-term infection of the host 
with sporadic reactivation to ensure transmission. In order to enable long-term latency, MHV-
68 has developed several strategies common among gamma-herpesviruses and some specific 
to MHV-68 to overcome i) host immunity and ii) apoptosis of infected cells. 
As discussed in the above chapter, a variety of immune mechanisms contribute to the 
control of MHV-68 infection, but cytotoxic activity of CD8+ T-cells seems to be one of the 
most efficient. To counteract CD8+ T-cell activity is especially important during lytic 
infection when many viral genes are expressed and antigens are abundant. 
MHV-68 interferes with CD8+ T-cell activation by inhibiting MHC class I-dependent 
antigen presentation. Mouse embryonic fibroblasts expressing a specific CTL epitope are 
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protected from lysis after infection with MHV-68. Detailed analysis of the MEFs revealed 
that the expression of MHC class I proteins on the surface was strongly reduced after MHV-
68 infection and genetic analysis identified viral protein MK3 as the mediator of MHC-I 
suppression [95]. MHV-68 encoded protein MK3 locates to the endoplasmatic reticulum 
where it binds H-2D chains via a zinc-finger binding motif and targets them for proteasomal 
degradation [96]. In vivo, MK3 is expressed both during lytic replication as well as during 
latency establishment in the spleen. A recombinant virus deficient for MK3 was cleared from 
the lungs with similar kinetics as a wt strain, however, the number of latently infected 
splenocytes was reduced while the frequency of MHV-68-specific CTLs was increased, 
indicating that interference with MHC class I-dependent antigen presentation is important 
during latency expansion in the spleen [97]. 
Downregulation of MHC class I expression on the surface of infected cells in order to 
evade T-cell recognition is also found in other members of the gamma-2-herpesvirus family, 
albeit through slightly different mechanisms. KSHV expresses two proteins, K3 and K5, that 
reduce MHC class I on the surface of infected cells by triggering rapid endocytosis of HLA 
chains [98,99]. 
Another strategy to evade host immune response, which is employed by many viruses, 
is interference with chemokine signaling. Chemokines regulate the recruitment of leukocytes 
to the site of inflammation, and herpesviruses have been shown to intervene in this process by 
expression of chemokine homologs (KSHV, hCMV, mCMV) and chemokine receptor 
homologs (KSHV, HVS, MHV-68, CMV) [100]. MHV-68 has an additional mechanism that 
is so far not known of any other herpesvirus. The gene M3 encodes a 44-kD secreted protein 
that exhibits broad-spectrum chemokine-binding properties, a feature also described in 
poxviruses. M3 binds to members of all chemokine subfamilies and blocks interaction with 
high-affinity receptors, preventing intracellular chemokine signaling and calcium influx 
[101,102]. It is expressed during acute infection and early latency [103] and is necessary for 
the establishment of normal latent viral load. Disruption of M3 does not change viral titers or 
the course of acute infection in the respiratory tract, but virus-driven activation of B-cells 
typical for the infectious mononucleosis-like syndrome is greatly reduced in the spleen and 
consequently there are far fewer cells positive for viral-tRNA. Depletion of CD8+ T-cells 
restored the levels of splenocytes infected with the M3-deficient virus to levels of the wild-
type strain, suggesting that the main role of M3 during latency amplification is to protect 
infected cells from CTLs [104]. Even though M3 is mainly expressed at early times post 
infection and not long-term latency, it might also be implicated in MHV-68-associated 
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lymphomagenesis as it has been shown to efficiently protect tumor cells from CTL attack. 
Supernatant of tumor cells transfected with M3 are able to inhibit migration of tumor-specific 
CTL in vitro, and secretion of M3 protects transfected tumor cells and surrounding cells from 
otherwise effective tumor-specific CTLs in vivo [105]. 
Besides the described CD8+ T-cell evasion, gamma-herpesviruses have a tendency to 
interfere with intracellular IFN type I signaling. Type I IFNs do not only promote 
inflammation by activating lymphocytes, NK-cells and macrophages but also have auto-and 
paracrine functions that induce antiviral effects in infected cells such as inhibition of RNA 
expression and protein synthesis, degradation of mRNA and induction of apoptosis. To 
counteract IFN type I signaling, MHV-68 expresses an enzyme (ORF54) which induces 
degradation of the type I interferon receptor IFNAR [106]. Experimental infection of mice 
with a recombinant virus deficient for ORF54 revealed only slightly elevated viral titers in the 
lung but a substantial reduction in splenic infection 14 days post inoculation, underscoring the 
importance of blocking type I IFN signaling in order to establish latency. To further disrupt 
IFN function, MHV-68 encodes a kinase (ORF36) that inhibits IFN expression by binding to 
IRF3, a transcription factor that activates IFN promoters [107]. Homologs of ORF36 are 
found in all members of the herpesvirus family [108] and their ability to suppress IRF3 
function is conserved in all gamma-herpesviruses [109,110], illustrating the evolutional 
pressure to disturb IFN function. 
Apoptosis is a highly efficient defense mechanism to limit viral replication and 
persistence that herpesviruses must overcome in order to establish long-term infection. 
Consequently, all lymphotropic herpesviruses have evolved strategies to inhibit induction of 
apoptosis in the host cell [111]. Apoptosis can be triggered not only by cytolytic effector cells 
but also through cell intrinsic pathways in response to metabolic stress or DNA damage 
which can be induced by excessive replication of intracellular pathogens.  
The balance between pro- and anti-apoptotic members of the bcl-2 protein family 
regulates the cell intrinsic pathways leading to apoptosis and homologues to bcl-2-family 
proteins that encode characteristic BH1 and BH2 domains have been found in all gamma-
herpesviruses. In contrast to cellular bcl-2 proteins that can be converted to potent pro-
apoptotic molecules through caspase-mediated cleavage, herpesviral bcl-2 homologues cannot 
be cleaved by caspases and thus retain their anti-apoptotic potential [112]. 
EBV gene product BHRF1 colocalizes with bcl-2 in vitro and protects cells from apoptosis 
[113], ORF16 from HVS and KSHV are v-bcl-2 proteins that dimerize with bcl-2 to suppress 
apoptosis [114,115] and in MHV-68, a putative viral bcl-2 was identified in M11. Even 
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though homology to bcl-2 and EBV BHRF1 is limited, functionality of the protein is 
conserved as M11 was shown to inhibit apoptosis induced by anti-Fas antibody or tumor 
necrosis factor α (TNF-α) when transfected into HeLa cells [116]. M11 is expressed together 
with early transcripts during lytic infection of fibroblasts in vitro, probably playing a role in 
survival of productively infected cells to ensure maximal viral replication. In vivo, M11 
transcripts are abundant in lung and spleen tissue at 2 weeks post infection together with other 
lytic gene products such as ORF50 and gp150, reflecting expression during lytic replication 
[117]. Interestingly, M11 transcripts are also found 10 months post infection in the spleen and 
lungs of infected mice, while other lytic transcripts are absent, indicating that M11 is also 
expressed during long-term latency where it might serve to protect infected cells from Fas-
mediated lysis by cytotoxic immune cells. Due to their ability to inhibit programmed cell 
death, herpesviral bcl-2 homologues might not only be important as an immune evasion 
mechanism for the establishment of life-long infection, but also play a major role in the 
ontology of gamma-herpesvirus-associated cancers. 
 
MHV-68 and lymphomagenesis 
One of the hopes put into the MHV-68 mouse model is to be able to study the oncogenic 
properties of gamma-herpesviruses and to understand how persistent infection is linked to 
lymphomagenesis in the host. However, there seem to be substantial differences in the 
oncogenic potential between the two subgroups of gamma-herpesviruses. Originally, it was 
assumed that only members of the subgroup lymphocryptovirus, to which EBV belongs, are 
able to growth transform primary B-cells in vitro, while B-lymphotropic rhadinoviruses 
MHV-68 and KSHV were not. Studies of the immortalization of B-cells by EBV identified a 
set of nine latency genes (EBNA1-6; LMP1; LMP2A; LMP2B) that in concert regulate the 
transformation to proliferating lymphoblastoid cell lines and were therefore termed the 
growth program [118]. In rhadinoviruses, there is no evidence for an analogous growth 
program and even though latency-associated genes have been identified in both KSHV and 
MHV-68, there are no homologues to the EBV latency genes. Still, KSHV is associated with 
several forms of cancer in humans [8,9] and experiments with T-lymphotropic rhadinoviruses 
Herpesvirus saimiri and Herpesvirus ateles showed growth-transformation of primary T-cells 
in vitro, proving that members of this subclass are very well oncogenic [119,120]. Indeed, a 
recent study has shown that MHV-68-infection of progenitor B-cells isolated from murine 
fetal liver results in proliferating plasmablasts that retain the virus and can be propagated 
indefinitely, thus reminiscent of EBV-transformed lymphoblastoid cell lines [121]. 
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In vivo, chronic long-term infection with MHV-68 was reported to be associated with 
increased incidence of lymphoma. In BALB/c mice, 9% of infected animals developed 
lymphoproliferative disorders including high-grade lymphomas in lymph nodes, spleen, liver 
and kidney [122]. Histological characterization revealed a mixed composition of B- and T-
cells in most cases and only very few cells stained positive for viral genome by in situ 
hybridization. The development of lymphoma seems rather slow, with the earliest tumors 
found 6 months after infection and most only after 2 years and more. Immunosuppressive 
treatment using cyclosporin A increased tumor frequency to 50% but did not accelerate the 
process of tumorigenesis. Afterwards, research mainly focused on lymphoma models utilizing 
mouse strains with variable genetic immunodeficiencies. Infection of BALB/c mice deficient 
for β2-microglobulin (β2m-/-) that lack a functional CD8+ T-cell response increased the 
incidence of lymphoma to 67% in comparison to 22% in mock infected controls over a 
timeframe of about 8-9 months [123]. Consistent with earlier observation, only a small 
number of lymphoma cells stained positive for viral tRNAs, indicating that MHV-68-
associated lymphomagenesis does not require constant presence of virus in the transformed 
cells but rather a "hit-and-run" type of transformation, in contrast to EBV-associated endemic 
Burkitt's Lymphoma where usually a vast majority of cancer cells carry viral genome. 
Notably, long-term infection of a mouse strain with different genetic background (129) 
bearing the same genetic deficiency (β2m-/-) did not result in any lymphoma over a timeframe 
of 1.5 years, confirming the impression that MHV-68 infection and pathology are strain-
dependent (see above). In IFNg-receptor deficient C57BL/6 mice, MHV-68 infection was 
associated with high incidence of inflammatory lesions in the lungs that progressed to 
pulmonary lymphoma in 45% of mice, a pathology similar to Lymphomatoid granulomatosis, 
a rare EBV-associated lymphoproliferative disease in human patients [66]. 
Evidence from long-term infection in vivo suggests that lymphoproliferative diseases 
are not a likely outcome of MHV-68 infection in immunocompetent hosts, presumably 
because i) MHV-68 lacks latency genes to efficiently growth-transform its host cell, and ii) 
adaptive immune responses are efficient at eliminating cells that undergo virus-driven 
hyperproliferation. So far, the only MHV-68 gene to show oncogenic potential comparable to 
EBV latency genes is the viral cyclin D homologue (ORF72), which drives cell cycle 
progression when expressed in thymocytes and leads to lymphoma in ORF72-transgenic mice 
[124]. In contrast to the EBV latency genes however, ORF72 is expressed at late times during 
lytic infection of fibroblasts but was so far not found during latent infection [125].  
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Immune control of MHV-68 associated tumors was investigated using B-cells 
immortalized by MHV-68 in vivo or in vitro that are able to establish growing tumors in 
immune deficient nude mice. In BALB/c nude mice, adoptive transfer of CD4+ T-cells led to 
a regression of tumors caused by injection of MHV-68 infected B-cell lymphoma S11, while 
adoptive transfer of CD8+ T-cells and B-cells was not effective [126]. In contrast, both CD4+ 
and CD8+ T-cells were effective at controlling the outgrowth of B-cells immortalized by 
MHV-68 infection in vitro when transferred into rag2-/- C57BL/6 mice [127]. 
To test oncogenic properties of other strains of murid Herpesvirus 4, long-term 
infection experiments were conducted with MHV-72, a strain isolated at the same time as 
MHV-68. Formation of neoplasms was reported in BALB/c mice at a rate similar to MHV-68 
(13% vs 9%) at equally late times post infection [128]. Consistent with the findings from 
MHV-68, the incidence of MHV72-associated lymphoma can be increased by 
immunosuppressive drugs [129]. 
 
 
Toll-like Receptors 
 
Toll-like receptors in innate immunity 
Innate immune mechanisms constitute the first line of defense against invading 
microorganisms, are crucial for mounting a rapid innate immune response and to shape the 
slower primary adaptive immune response. The innate immune system recognizes pathogens 
via an array of germline-encoded pattern-recognition receptors (PRRs) that are triggered by 
common molecular structures of bacterial, viral, fungal, or parasitic pathogens. PRRs initiate 
signaling pathways that lead to the expression of microbicidal molecules and pro-
inflammatory cytokines. 
The first family of PRRs to be described was the Toll-like receptor family (TLRs), 
named after the Toll protein of the fruitfly (Drosophila melanogaster). Originally described 
as an important factor in embryonal dorso-ventral patterning of Drosophila [130], it was 
found that the Toll protein is also essential in the protection from fungal infections [131], 
indicating its role in innate immunity. Toll-like receptors are an evolutionarily conserved 
mechanism present in all mammals and the first homologue to the Toll protein of Drosophila 
in humans was found soon after [132]. To date there have been 10 and 12 TLRs identified in 
humans and in mice, respectively, with TLR1-TLR9 being conserved in both. Ligands for all 
TLRs except TLR10 have been identified and each TLR recognizes certain pathogen-
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associated molecular patterns (PAMPs) including lipids, lipoproteins and nucleic acids that 
are present in pathogens such as bacteria, viruses, fungi and protozoa. 
TLRs are membrane-spanning receptors that consist of an ectodomain containing 
leucine-rich repeats that are responsible for recognition of the ligand, a transmembrane 
domain and a cytoplasmic tail containing Toll-Interleukin 1 (IL1) receptor (TIR) domains that 
allows binding of distinct adaptor molecules for signal transduction [133]. Signal transduction 
via different cellular kinases ultimately leads to the activation of transcription factors that 
regulate the expression of pro-inflammatory cytokines, anti-viral effector molecules such as 
type I Interferon and upregulation of co-stimulatory receptors on cells of the adaptive immune 
system [134]. 
TLRs can be broadly divided into two groups based on their location on either the 
plasma membrane or the endosomal compartment. TLRs 1, 2, 4, 5, 6, 10 are located on the 
plasma membrane where they recognize predominantly hydrophobic structures such as 
proteins, lipopeptides and polysaccharides, whereas TLRs 3, 7, 8, 9 are located almost 
exclusively in the endosome where they sense different forms of nucleic acid [135]. 
 
Toll-like receptors and gamma-herpesviruses 
Several members of the TLR family have been shown to sense gamma-herpesvirus infection. 
Since nucleic acids are the most potent immune stimulatory component of viruses, the TLRs 
mainly involved in herpesvirus recognition are the endosomal TLRs 3, 7, and 9. TLR9 
recognizes unmethylated CpG motifs that are relatively rare in vertebrate DNA but 
abundantly present in herpesviral genomes and senses members from all herpesvirus 
subgroups [136,137] including EBV [138]. The ligand of TLR3 is double-stranded RNA, a 
molecular pattern that is not inherently present in herpesvirus genomes but can be generated 
as intermediate structures during replication and act as TLR3 agonist [139]. In the case of 
EBV, latency-associated EBV-encoded small RNAs (EBERs) are an additional ligand for 
TLR3 [140]. TLR7 is responsive to single-stranded RNA and has been reported to 
complement TLR9 signaling to generate an efficient immune response against murine 
Cytomegalovirus even though the exact nature of the viral agonist is not known [141]. 
TLR7 and TLR9 share a common signaling pathway through recruitment of adaptor 
molecule myeloid differentiation primary response protein 88 (MyD88) that binds to the 
cytoplasmic tail of activated TLRs via a homologous TIR-domain. MyD88 activates IL1-
receptor-associated kinases (IRAKs) and tumor-necrosis-receptor-associated-factor 6 
(TRAF6) that activate Inhibitor of nuclear factor κB-kinase complex (IKK-complex) (Fig.4).  
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Figure 4. Signaling pathways of endosomal Toll-like receptors. TLR7 and TLR9 share a common signaling 
pathway through myeloid differentiation primary response protein 88 (MyD88), activation of IL1-receptor-
associated kinase 1 (IRAK1) and tumor-necrosis-receptor-associated-factor 6 (TRAF6). Subsequent activation of 
Inhibitor of nuclear factor κB-kinase complex (IKK-complex) frees NFκB from its inhibitor IκB and allows 
nuclear translocation where expression of pro-inflammatory cytokines is induced. TLR3 signals via TIR-
domain-containing adaptor molecule inducing IFN-β (TRIF), IKK-ε and TANK-binding kinase 1 (TBK1) to 
activate Interferon regulatory factor 3 (IRF3) which induces expression of IFN-β. Adapted from Akira & 
Takeda, Nat Rev Immunol. 2004 [142] 
 
The transcription factor NFκB is released from its inhibitor in the cytoplasm and 
translocates to the nucleus where it induces expression of pro-inflammatory cytokines. TLR3 
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uses a different adaptor molecule, TIR-domain-containing adaptor molecule inducing IFN-β 
(TRIF), to relay its signal to IKK-ε and TANK-binding kinase 1 (TBK1) which activate 
Interferon regulatory factor 3 (IRF3) and induce expression of IFN- β (reviewed in [142]). 
Signaling via endosomal TLRs and activation of NFκB transcription factors in the 
context of gamma-herpesvirus infection is not only important due to its role in the induction 
of host immune responses. There is evidence that TLR signaling contributes to shaping viral 
gene expression and thus the balance between lytic replication and latency. Earlier studies in 
our lab found that stimulation of Burkitt's lymphoma cells with synthetic ligands to TLR9 
suppresses EBV reactivation in vitro [143,144] and transfection of NFκB subunit p65 was 
reported to inhibit expression of gamma-herpesvirus lytic genes by directly interacting with 
the promoter sequence of the master lytic regulator gene [145]. Conversely, synthetic ligands 
to TLRs 3 and 9 were reported to induce reactivation of both MHV-68 and KSHV in vitro 
[146,147], suggesting that TLR stimulation might play a role in viral replication. 
Additionally, activation of the NFκB axis has a range of effects on lymphocytes, controlling 
immune cell proliferation and survival by inducing expression of the growth factor interleukin 
6 (IL6) and tumor-necrosis factor (TNF) [148].  
The properties of TLR-mediated NFκB signaling are of particular interest in the 
context of gamma-herpesvirus infection, as they might turn out to be a double-edged sword: 
on the one hand they are crucial for the induction of an adaptive immune response, on the 
other hand they might facilitate establishment of long-term infection and lymphomagenesis 
through induction of proliferation and survival of infected B-lymphocytes. Thus, stimulation 
of TLR pathways offers a possible explanation as to how co-infections might disturb the 
balance between infection and immune control in asymptomatic long-term latency and 
contribute to the ontology of gamma-herpesvirus- associated lymphoma in immunocompetent 
patients. 
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Subject of Investigation 
 
The subject of this thesis was to investigate the impact of recurrent innate immune stimulation 
via endosomal Toll-like receptors on gamma-herpesvirus infection and lymphomagenesis 
using MHV-68 as a model. To adress this subject, the following topics were investigated: 
 
1.  Does long-term infection of MHV-68 in immune deficient mice lead to development 
 of lymphoproliferative disease? 
 
Long-term infection with MHV-68 in mice has been associated with lymphoproliferative 
disorders similar to the human gamma-herpesviruses EBV and KSHV. Such a model would 
be valuable to investigate the ontology of gamma-herpesvirus-associated cancer. Since MHV-
68 is not transforming in vitro and lymphomagenesis in immunocompetent mice is inefficient, 
we tested the outcome of long-term infection in mice with specific immune deficiencies. 
 
2. How does stimulation of endosomal Toll-like receptors impact on MHV-68 infection 
 in vitro and in vivo? 
 
Toll-like receptor signaling affects host B-cells as well as viral gene expression. Studies in 
our lab have shown that TLR9 signaling suppresses EBV reactivation in Burkitt's lymphoma 
cells in vitro. We tested the outcome of constant TLR stimulation on MHV-68 in vitro and in 
vivo using synthetic ligands for endosomal TLRs 7 and 9. 
 
3. Does the compound hemozoin derived from the malaria parasite Plasmodium 
 falciparum mimick the impact of TLR stimulation on MHV-68 gene expression? 
 
Endemic Burkitt's Lymphoma is associated with both EBV infection and holoendemic 
transmission of the parasite Plasmodium falciparum, the causative agent of Malaria tropica. 
Hemozoin is a waste product of Plasmodium metabolism in parasitized red blood cells and is 
constantly released into the bloodstream. Since hemozoin is a suspected ligand of TLR9, we 
hypothesized that Plasmodium infection impacts on gamma-herpesviruses by stimulating 
TLR pathways. We tested whether hemozoin mimicks the effect of synthetic TLR9 ligand on 
MHV-68 gene expression. 
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Results 
 
MHV-68 latent infection is increased in mice with distinct immune deficiencies but 
lymphoproliferative disease is absent 
 
Long-term MHV-68 infection is associated with lymphoproliferative disorders in mice and 
immune suppressive treatment has been reported to increase the incidence of malignancies. 
To study latent MHV-68 infection in immunocompromised mice, cohorts of C57BL/6 wild-
type mice and congenic knock-out mice with distinct immune deficiencies were infected by 
intra-peritoneal injection. The knock-out mice used for this experiment were CD8-/-, CD4-/- or 
TLR9-/-. Three months post infection, mice were sacrificed and the frequency of infected 
splenocytes was measured by limiting-dilution nested PCR to assess establishment of latent 
infection (Fig. 5). 
 
Figure 5. Intraperitoneal injection of MHV-68 leads to the establishment of latent infection in splenocytes in 
vivo. C57BL/6 wild-type and congenic knock-out mice (n=4 mice for each group) were infected with MHV-68 
by i.p. injection. Splenocytes isolated from infected mice at 3 months post infection were analyzed by limiting-
dilution nested PCR targeting ORF72. Data are expressed as mean percentages of positive reactions ±SD. 
Sigmoidal dose-response curve was fit by nonlinear regression analysis using GraphPad software. From the 
equation of the curve, the intersection with the dotted line at 63.2% was calculated and the frequency of MHV-
68 positive splenocytes was assessed based on Poisson distribution. Calculated frequencies for each group are 
shown in the graph (number in the box). EC50 values of single curves were compared for statistical analysis 
using t-test (wt vs. CD4-/- p=0.005; wt vs. CD8-/- p=0.003; wt vs. TLR9-/- p=0.12). 
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In wild-type mice the frequency of infected splenocytes was about 1:20'000 cells. In 
mice with deficiencies in T-cell subsets (CD4-/-, CD8-/-), the frequency of splenocytes positive 
for viral genome was significantly elevated up to 10-fold, indicating a loss of immune control 
over latent infection. Nevertheless, none of the animals showed signs of clinical illness over 
the course of the experiment, suggesting that while a partial loss of immune control leads to 
higher levels of infection, redundant mechanisms protect the host from harmful disease. Mice 
lacking Toll-like receptor 9 showed a tendency to lower frequencies of infected cells, 
eventhough this difference was not significant. Notably, no infectious virus was detected in 
the spleens of any of the infected animals by plaque assay, indicating predominantly latent 
infection. After having confirmed successful establishment of latency in immunodeficient 
mice, infection was allowed to progress in two cohorts of infected CD4-/- and CD8-/- to 
investigate possible lymphoma formation. Health status of all animals was checked in weekly 
intervals. 11 months post infection, there was no sign of lymphoproliferative disorders and the 
experiment was terminated. All animals were sacrificed and analyzed post mortem for signs 
of lymphoma as well as limiting-dilution analysis of infected splenocytes (Fig. 6).  
Figure 6. Frequencies of MHV-68 positive splenocytes in immune deficient mice are stable up to 11 months 
post infection. Knock-out mice on a C57BL/6 background (n=3 for CD4-/-; n=4 for CD8-/-) were infected with 
MHV-68 by i.p. injection. Splenocytes isolated from infected mice at 11 months post infection were analyzed by 
limiting-dilution nested PCR targeting ORF72. Data are expressed as mean percentages of positive reactions 
±SD. Sigmoidal dose-response curve was fit by nonlinear regression analysis using GraphPad software. From 
the equation of the curve, the intersection with the dotted line at 63.2% was calculated and the frequency of 
MHV-68 positive splenocytes was assessed based on Poisson distribution. Calculated frequencies for each group 
are shown in the graph (number in the box). 
 
Frequencies of infected cells at 11 months post infection did not differ significantly 
from the respective frequencies measured at 3 months post infection, suggesting that the level 
of latent infection is rather stable at least up to one year after initial infection. No signs of 
lymphoproliferative disorder were found post mortem. 
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Abstract 
Latent gamma-herpesvirus infection is associated with various B-cell lymphoma. In order to 
understand and possibly treat herpesvirus-associated malignancies, it is vital to understand the 
factors that control the balance between the two transcriptional states of gamma-
herpesviruses, lytic replication and latency. In this study, we used murine gamma-herpesvirus 
(MHV)-68 as a model system to investigate how engagement of endosomal Toll-like 
receptors (TLR) impacts on reactivation in vitro and establishment of latent infection in vivo. 
We found that treatment with TLR7 ligand R848 and TLR9 ligand CpG ODN suppresses 
reactivation of MHV-68 in vitro and that this effect correlates with the ability to activate the 
transcription factor NFκB. In vivo, continuous stimulation of TLR7 by R848 treatment led to 
an increased frequency of infected splenocytes compared to mock-treated control. 
Downregulation of TLR9 by RNA interference in vitro reduced nuclear levels of NFκB p65 
and consequently increased spontaneous reactivation in MHV-68 latently infected cells, 
indicating that the TLR9 pathway contributes to limiting spontaneous reactivation events. 
Frequencies of infected splenic B-cells in tlr7-/- or tlr9-/- mice did not differ from their wild-
type counterpart. However, infected B-cells from tlr9-/- mice showed a higher frequency of 
reactivation compared to wild-type or tlr7-/- in an ex vivo reactivation assay. Our results show 
a suppressive effect of TLR7 and TLR9 signaling on MHV-68 reactivation and demonstrate 
that TLR9 signaling pathway is constantly active in infected cells, thereby contributing to 
NFκB activity and suppression of lytic replication. 
 
 
for detailed information, see attached manuscript 1 
Results 
31	  
 
Hemozoin Extracted from Plasmodium falciparum Cultures Suppresses Gamma-
Herpesvirus Reactivation in vitro 
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Abstract 
Endemic Burkitt's lymphoma (eBL) is the most common pediatric cancer in equatorial Africa. 
It is associated with the gamma-herpesvirus Epstein-Barr virus and only occurs in regions 
where the malaria parasite Plasmodium falciparum is holoendemic. Thus eBL is suspected to 
be a polymicrobial disease. Although association with both EBV and malaria is established, 
the exact mechanism how chronic P. falciparum infection impacts on usually asymptomatic 
EBV and promotes incidence of EBV-positive cancer is unknown. Here, we show that 
hemozoin, a waste product of parasite metabolism extracted from P. falciparum cultures in 
vitro, suppresses lytic reactivation from latency in both EBV-infected BL cells as well as 
mouse lymphoma cells infected with murine gamma-herpesvirus 68. Suppression of viral 
reactivation was only seen when cells were stimulated with natural hemozoin extract but not 
with synthetic analogue β-hematin. Suppression of lytic reactivation promotes latency and has 
been shown to increase the frequency of infected cells in vivo. We hypothesize that chronic 
malaria contributes to the incidence of eBL by suppressing EBV reactivation via constant 
shedding of hemozoin to the bloodstream and therefore increasing the pool of latently 
infected B-cells. 
 
 
for detailed information, see attached manuscript 2 
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Discussion and Outlook 
 
MHV-68 infection of mice provides researchers a much-needed small and tractable animal 
model for gamma-herpesvirus infection, given that human gamma-herpesviruses can be 
studied in vivo only in non-human primates. The high degree of genetic homology among 
gamma-herpesviruses and the similarity in host cell subset tropism and viral life cycle makes 
MHV-68 a useful model system, despite minor concerns about infection in lab mice not 
properly reflecting the events in a natural host such as wood mice. The availability of 
genetically engineered mouse strains in conjunction with recombinant viruses enables 
uniquely detailed investigations of the importance of single cellular pathways or viral genes 
during different steps of host colonization. From what we know so far, it is reasonable to 
assume that events such as the resolution of acute infection and the immune control of latent 
MHV-68 are representative of gamma-herpesviruses in general and reflect universal concepts 
that are vital to understand in order to comprehend host-virus interaction. MHV-68 infection 
of mice therefore is an optimal tool to elucidate gamma-herpesvirus biology and host immune 
responses. 
The long-term infection studies we performed using knock-out mice of different 
immune elements provide an example how the model can be used to investigate establishment 
of latency and control of persistent infection under very specific, well-defined conditions of 
immune deficiency. Our results illustrate how distinct arms of the immune system control 
gamma-herpesvirus infection. Even though infection levels were increased in immune 
deficient mice, no pathological signs of illness were observed, suggesting that redundant 
mechanisms of immune surveillance clear acute infection and control latent virus. We found 
the highest frequencies of infected splenocytes in mice lacking cytotoxic CD8+ T-cells, a 
subset of immune cells that is important in controlling both acute and latent infection [81]. 
Mice lacking CD4+ T-cells also showed a phenotype with higher levels of infected 
splenocytes, even though not as pronounced as CD8-/- mice. Interestingly, levels of latently 
infected splenocytes were rather constant over the timespan of the experiment, indicating that 
a balance was established between MHV-68 infection and immune control where various 
immune mechanisms contribute to maintaining latency at distinct levels. 
Despite increased levels of latent MHV-68 infection in immune deficient mice, 
lymphoma formation was not observed until 11 months post infection. Therefore, although 
our sample size was small, the use of MHV-68 seems not to be apt to study pathogenic 
mechanisms of gamma-herpesvirus-associated lymphoma. Lymphoproliferative disorders 
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following MHV-68 infection seem to be very rare and slow to develop [122], rendering the 
respective studies rather cumbersome and unreliable. In β2-microglobulin-/- BALB/c mice that 
lack a functional CD8+ T-cell response, the incidence of lymphoma was increased to 67% 
after only 9 months of infection [123], an observation we could not confirm in CD8-/- mice 
from C57BL/6 background. It is worth noting that all MHV-68-associated lymphoma in 
immunocompetent mice reported so far have been observed in BALB/c mice, which indicates 
a substantial contribution of the genetic background to the susceptibility to lymphomagenesis. 
This makes general conclusions about the pathogenesis of MHV-68 difficult and the mouse 
genetic background should be considered in future experimental approaches. 
MHV-68 lacks both the transforming potential of EBV in vitro as well as a distinct 
latency program of gene expression that defines various lymphoproliferative disorders caused 
by EBV in humans. For these reasons, it might be better to rely on other models for the study 
of EBV-associated lymphomagenesis such as reconstitution of a human immune system in 
immunodeficient mice and subsequent infection with EBV as described by Strowig et al. 
[149] or to use transgenic mice to model BL-like cancers through expression of the myc 
oncogene and EBV latent gene products like LMP2A [150,151]. 
Signaling via Toll-like receptors impacts on gamma-herpesvirus lytic gene expression 
and reactivation and it is therefore important to examine the associated signaling pathways in 
vivo. As shown by earlier studies in our lab using BL cells as a model [143], triggering of 
TLR9 invariably suppresses EBV reactivation. Using the MHV-68-infected cell line S11, we 
were able to confirm this interaction in vitro, indicating that it is not restricted to EBV but it is 
rather a general mechanism shared by gamma-herpesviruses. In contrast to the BL cell model, 
we unprecedentedly found that triggering of TLR7 also has the capacity to suppress 
spontaneous as well as induced reactivation (see manuscript 1). It is not surprising that TLR7 
and TLR9 would have a comparable effect when stimulated, since they share a signaling 
pathway via the common adaptor molecule MyD88, which culminates in the activation of the 
transcription factor NFκB. Indeed, the suppressive effect on MHV-68 lytic genes correlated 
with the ability to induce NFκB activation, while TLR9-mediated suppression of EBV was 
independent of NFκB activation and was instead mediated by histone modifications on EBV-
associated chromatin. It is interesting that two gamma-herpesviruses that diverged in their 
evolution about 60 million years ago retained the same feature but execute it via different 
mechanisms. This would imply that suppression of lytic genes via TLR stimulation is an 
important aspect of gamma-herpesvirus biology and confers significant advantages in 
biological fitness. 
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After having confirmed the suppression of lytic MHV-68 by endosomal TLR signaling 
inducing NFκB activation, we were able to study the consequences of repeated TLR 
stimulation in vivo. The treatment of infected mice with synthetic TLR7 ligand caused a 
significant increase of latently infected cells, suggesting that innate immune stimulation via 
TLR signaling is indeed reinforcing latency establishment rather than having an anti-viral 
effect for the host. Based on our observations in vitro, we hypothesize that activation of 
endosomal TLR pathways promotes establishment of latent infection by limiting initiation of 
lytic replication while concurrently enabling proliferation and survival of latently infected B-
cells [152]. Activation of the transcription factor NFκB does not only seem to be beneficial 
but rather a prerequisite for MHV-68 latency, since a recombinant MHV-68 that expresses 
IκBαM, a constitutively active form of the NFκB inhibitor, exhibited severely impaired 
establishment of latency in the spleen [72]. 
Since TLR9 in particular was reported to sense MHV-68 directly [153], we speculated 
that activation of TLR pathways by viral infection itself might contribute to the NFκB 
activation necessary for successful establishment and maintenance of latent infection. Indeed, 
downregulation of TLR9, but not TLR7, in S11 cells reduced NFκB activation in S11 cells 
and led to increased reactivation in vitro. Due to the relatively high rate of spontaneous 
reactivation in S11 cells and the resulting high levels of viral particles in the supernatant, we 
were not able to discern if viral particles in the supernatant or latent viral genomes are 
responsible for the intrinsic activation of the TLR9 pathway. Nevertheless, our observations 
indicate that MHV-68 has developed a strategy to usurp innate immune sensing to create a 
favorable environment for latent infection and use it to its own advantage. In vivo, 
suppression of lytic MHV-68 genes mediated by NFκB induction during de novo infection 
might serve as a negative feedback loop with the potential to limit productive replication and 
initiate latency. Additionally, such a mechanism could function as a homeostatic regulator to 
locally limit reactivation from latency. While the frequency of latently infected splenocytes in 
tlr9-/- or tlr7-/- mice did not differ significantly from the wild-type controls, spontaneous 
reactivation events upon explant were more frequent in tlr9-/- B-cells, confirming that intact 
TLR9 signaling contributes to limit lytic replication. Importantly, other gamma-herpesviruses 
use activation of NFκB in the host cell to help latency establishment as evidenced by EBV’s 
binding to the cellular receptor CD21, which induces NFκB that in turn mediates activation of 
the viral latent gene promoter [154]. 
The finding that repeated or chronic stimulation of innate immune receptors can 
promote latent gamma-herpesvirus infection is particularly relevant when considering the role 
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of co-infections in the development of EBV-associated lymphoma. As shown before, repeated 
or continuous stimulation of TLRs during persistent infection in vivo increases the number of 
latently infected B-cells in mice. Notably, the numbers of EBV-infected B-cells in the blood 
of patients from regions holoendemic for malaria and with high incidence of BL are elevated 
in a similar fashion [155]. It is therefore conceivable that the repeated or constant immune 
activation caused by chronic malaria is an important factor in the etiology of eBL. In order to 
investigate this hypothesis, we started by testing if hemozoin, a putative TLR9 ligand released 
into the blood-stream of patients with P. falciparum infection has the potential to suppress 
lytic reactivation of EBV and MHV-68 in vitro (see manuscript 2). Our finding that natural 
hemozoin is able to suppress lytic viral gene expression in both viruses similar to TLR9 
ligand CpG suggests that high concentrations of hemozoin in the blood-stream might indeed 
explain the increased numbers of infected B-cells observed in the blood of human patients. 
The existence of Plasmodium species pathogenic for laboratory mice makes it possible to test 
this hypothesis in an in vivo setting in the future. 
Taken together, our results emphasize an important role of innate immune receptor 
signaling in promoting persistent infection of MHV-68 in B-cells and shows for the first time 
that TLR9 triggering by a gamma-herpesvirus itself might contribute to create a favorable 
host cellular environment for long-term latency. The impact of external TLR ligands on 
gamma-herpesvirus latency as observed in the MHV-68 model system are important not only 
as a possible link between EBV-associated lymphoma and co-infections such as P. 
falciparum, but also in the light of TLR ligands being increasingly used as adjuvants in the 
treatment of infectious diseases, cancer or autoimmunity, a practice which might 
detrimentally affect latent gamma-herpesvirus infections if administered chronically. 
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Abstract 
Latent gamma-herpesvirus infection is associated with various B-cell lymphoma. In order to 
understand and possibly treat herpesvirus-associated malignancies, it is vital to understand the 
factors that control the balance between the two transcriptional states of gamma-
herpesviruses, lytic replication and latency. In this study, we used murine gamma-herpesvirus 
(MHV)-68 as a model system to investigate how engagement of endosomal Toll-like 
receptors (TLR) impacts on reactivation in vitro and establishment of latent infection in vivo. 
We found that treatment with TLR7 ligand R848 and TLR9 ligand CpG ODN suppresses 
reactivation of MHV-68 in vitro and that this effect correlates with the ability to activate the 
transcription factor NFκB. In vivo, continuous stimulation of TLR7 by R848 treatment led to 
an increased frequency of infected splenocytes compared to mock-treated control. 
Downregulation of TLR9 by RNA interference in vitro led to reduced nuclear levels of NFκB 
p65 and consequently to increased spontaneous reactivation in MHV-68 latently infected 
cells, indicating that the TLR9 pathway contributes to limiting spontaneous reactivation 
events. Frequencies of infected splenic B-cells in tlr7-/- or tlr9-/- mice did not differ from their 
wild-type counterpart. However, infected B-cells from tlr9-/- mice showed a higher frequency 
of reactivation compared to wild-type or tlr7-/- in an ex vivo reactivation assay. Our results 
show a suppressive effect of TLR7 and TLR9 signaling on MHV-68 reactivation and 
demonstrate that TLR9 signaling pathway is constantly active in infected cells, thereby 
contributing to NFκB activity and suppression of lytic replication. 
 
Manuscripts 
51	  
INTRODUCTION 
Gamma-herpesviruses are double-stranded DNA B-lymphotropic viruses capable of 
establishing life-long latent infections. Epstein-Barr virus (EBV) is the most prominent 
human gamma-herpesvirus with a seroprevalence in the adult population of over 90%. Latent 
EBV infection is associated with B-cell malignancies including endemic Burkitt’s lymphoma 
and Hodgkin lymphoma in immunocompetent patients as well as lymphoma in 
immunocompromised patients (54). EBV’s oncogenic potential is demonstrated by 
transformation and induction of unrestricted proliferation of infected B-cells in vitro (20).  
One of the hallmarks of all gamma-herpesviruses is their sporadic reactivation from 
latent infection with subsequent production and release of new infectious particles (41). 
Sporadic reactivation is essential to ensure transmission to a new host but at the same time 
needs to be tightly controlled since the viral gene products represent a target for host 
immunity (37). 
Intrinsic and extrinsic factors are thought to control the balance between latent and 
lytic infection of gamma-herpesviruses. The innate immune system, in particular signaling via 
Toll-like receptors (TLRs), is thought to be essential in the balance between latency and 
reactivation (14, 16, 29, 56). TLRs are a family of pattern-recognition receptors (PRRs) that 
play a central role in innate immune activation (44). 
In mammals, four members of the TLR family are expressed almost exclusively in 
intracellular compartments (TLR3, TLR7, TLR8, and TLR9) (44), where they function as 
sensors for bacterial or viral nucleic acids (25). The natural ligand of TLR3 is double-stranded 
RNA while TLR7 senses single-stranded RNA, and TLR9 detects unmethylated DNA 
containing CpG motifs. TLR8 is structurally closely related to TLR7 and independently 
recognizes single-stranded RNA (23) but is thought to be biologically inactive in mice, 
instead having a regulatory function in modifying expression and signaling of TLR7 (8). 
Subsequent to ligation of the receptor, signaling is forwarded via the recruitment of specific 
Toll/IL-1 receptor (TIR)-domain containing adaptor proteins, myeloid differentiation primary 
response protein 88 (MyD88) in the case of TLR7 as well as TLR9 (32) and TIR-domain 
containing adaptor inducing IFN-β (TRIF) in the case of TLR3 (53). Eventually, signaling via 
TLRs 3, 7, and 9 leads to activation of the nuclear factor-κB (NFκB) axis which triggers pro- 
and anti-inflammatory cytokines (3). Importantly, activation of NFκB has been demonstrated 
to be crucial for the establishment and maintenance of latent gamma-herpesvirus infection in 
distinct ways. First, high levels of NFκB subunit p65 inhibit activation of lytic gene 
promoters of several gamma-herpesviruses (4, 22) and second, recombinant murine gamma-
Manuscripts 
52	  
herpesvirus 68 (MHV-68) expressing the constitutively active form of the NFκB-inhibitor 
IκBα is impaired in its ability to establish latent infection in vivo (28). Nevertheless and 
controversially, triggering of TLR3 and TLR9 were found to induce reactivation of MHV-68, 
while TLR7 did not (14), despite TLR7 and TLR9 sharing the same signaling pathway and 
even though TLR3, TLR7, and TLR9 are canonical activators of NFκB.. 
Many viruses including herpesviruses have evolved strategies to benefit from NFκB 
activation either directly by having NFκB binding sites in their promoters or indirectly by 
using the enhanced proliferation and survival of the host cell due to NFκB signaling to their 
advantage (39). TLR9 senses gamma-herpesviruses (12, 35, 51) and other herpesviruses (27, 
55) directly, but the implication of a potential NFκB activation via TLR9 signaling caused by 
infection with a gamma-herpesvirus itself has not been examined in detail. TLR7 was shown 
to recognize ssRNA viruses (9, 30), but also seems to contribute to the sensing of gamma-
herpesviruses in dendritic cells (35), likely mediated by viral RNA products. 
In the present study, we used MHV-68 to study the effect of endosomal TLR 
triggering and activation of NFκB on the expression of lytic viral genes and shedding of viral 
particles in vitro and on the establishment of latent infection in vivo. MHV-68 is commonly 
accepted as a model system to investigate gamma-herpesvirus infection in vivo, since it is 
highly homologous to the human gamma-herpesviruses EBV and Kaposi sarcoma-associated 
Herpesvirus (KSHV) (48). We aimed at advancing the mechanistic understanding of the 
impact of TLR stimulation on spontaneous reactivation from latent infection using a cell line 
harboring latent MHV-68. Further, we tested whether TLR7 or TLR9 signaling contributes to 
NFκB activation in latently MHV-68-infected cells and impacts on viral behavior both in 
vitro and in vivo. 
 
MATERIAL AND METHODS 
Ethics Statement. All animal experiments were done according to the guidelines of the 
Animal Welfare Act provided by the Swiss Federal Veterinary Office (www.bvet.admin.ch), 
and by the veterinarian authorities of the Canton of Zurich, Switzerland approved all 
procedures (License Nr. 100/2012). 
 
Cell culture and MHV-68 viral production. The MHV-68-infected murine B-cell line S11 
(courtesy of Prof. Ren Sun, Los Angeles, CA) was cultured in RPMI 1640 medium 
supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% penicillin-streptomycin 
and 2mM L-glutamine; baby hamster kidney cells (BHK-21) (6) (courtesy of Prof. A. Nash, 
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University of Edinburgh, UK) were cultured in Glasgow minimal essential medium (GMEM) 
supplemented with 10% Tryptose Phosphate Broth, 10% heat-inactivated FCS and 1% 
penicillin-streptomycin; murine fibroblast cells NIH3T12 (courtesy of Prof. S. Speck, Emory 
Vaccine Center, GA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% heat-inactivated FCS, 1% penicillin-streptomycin and 2mM L-
glutamine (all reagents from Invitrogen, Basel, Switzerland). 
Wild type MHV-68 clone g2.4 (11) (courtesy of Prof. Ren Sun, Los Angeles, CA) was 
grown in BHK-21 cells (43). Cells and supernatant were harvested at 7 dpi, centrifuged at 
1,400 rpm for 5 min, and the supernatant was passed through a TPP PES 0.22μm filter 
(Omnilab, Mettmenstetten, Switzerland) and stored at -80°C. MHV-68 titers were determined 
by plaque assay on BHK-21 cells. 
 
Mice. C57BL/6 mice were purchased from Harlan (The Netherlands). Tlr7-/- and tlr9-/- mice 
on a C57BL/6 background were obtained from the Swiss Immunological Mutant Mouse 
Repository (SwiMMR, Zurich, Switzerland). All animals were kept in a specific pathogen 
free environment. 
 
Detection of tlr gene expression. Gene expression of tlrs was determined by reverse 
transcription PCR using gene specific primers as described in (10) and gapdh gene expression 
was used as a loading control. 
 
TLR triggering. S11 cells were resuspended at 1×106 cells/ml of supplemented RPMI and 
stimulated with 25 μg/ml Poly(I:C), 3 μM of R848 or 0.5 μM of CpG ODN 1826 (Invivogen, 
San Diego, CA), 2 hours prior to stimulation with 10 ng/ml of 12-O-tetradecanoylphorbol-13-
acetate (TPA; Sigma-Aldrich, Buchs, Switzerland). 24 hours after treatment, cell pellets were 
assayed for MHV-68 lytic gene expression by qPCR and supernatants were tested for MHV-
68 production by plaque assay (see below). 
 
Reverse transcription and quantitative PCR. Expression of MHV-68 lytic genes ORF50, 
ORF21 and M7 was determined by quantitative polymerase chain reaction (qPCR) using ABI 
7900HT Fast Real-Time PCR System (Applied Biosystems, Rotkreuz, Switzerland). Total 
RNA was extracted from cells using RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland) 
and contaminating DNA was removed by DNAse treatment (DNA-free Ambion; Applied 
Biosystems, Rotkreuz, Switzerland). cDNA was synthesized using High Capacity cDNA 
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Reverse Transcription Kit (Applied Biosystems). Amplification of synthesized cDNA was 
performed using TaqMan® Gene Expression Master Mix (Applied Biosystems). The primers 
and probe sequences used for MHV-68 genes are indicated in Table S1. Primers and probes 
for tlr7 (Mm00446590_m1), tlr9 (Mm00446193_m1), ifnb1 (Mm00439552_s1), il-6 
(Mm99999064_m1), il-10 (Mm00439614_m1) and gapdh (Mm99999915_g1) were all from 
Applied Biosystems. 
 
Plaque assay. MHV-68 titers in supernatant of S11 cells were determined by plaque assay as 
described (43). BHK-21 cells were plated onto 6-well plates at 2 × 105 cells/well one day 
prior to infection. Serially diluted viral supernatants were placed onto monolayers and 
incubated for 1h at 37oC in 5% CO2. Supernatants were then removed and replaced with 
complete GMEM containing 1% methyl cellulose (Sigma-Aldrich). After 3-4 days, the 
monolayers were fixed with methanol, stained with neutral red solution (Sigma-Aldrich) and 
the numbers of plaques were counted. 
 
Preparation of nuclear extracts. 2×106 cells were washed with Tris-buffered saline (TBS) 
and cell pellet was resuspended in 800 μl cold cell lysis buffer (10 mM HEPES pH 7.9; 10 
mM KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM DTT; 0.5 mM PMSF), kept at 4oC for 15 
min, and vortexed for 10 seconds after 50 μl of a 10% solution of Nonidet P-40 (Roche, 
Mannheim, Germany) was added. The homogenate was centrifuged for 30 seconds, the 
nuclear pellet was re-suspended in 100 μl ice-cold nuclear lysis buffer (20 mM HEPES pH 
7.9; 0.4 M NaCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM DTT; 0.5 mM PMSF) and rocked at 
4oC for 15 min on a shaking platform. The nuclear extract was centrifuged for 5 min at 4oC 
and the supernatant was stored at -80oC. 
 
Western blot analysis. Nuclear extracts were analyzed by SDS-PAGE on a NuPAGE 10% 
Bis-Tris gel (Invitrogen). The proteins were transferred onto PROTRAN Nitrocellulose 
Transfer Membrane (Whatman, Kent, UK) and probed with specific antibodies against NFκB 
p65 (sc-8008, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), PCNA (sc-25280; Santa 
Cruz) and beta-actin (Cat. No. 4967, Cell Signaling Technology, Beverly, MA). GeneTools 
software (SynGene, Cambridge, UK) was used for densitometric analysis. 
 
Detection of spliced variant of ORF73. RNA isolation and cDNA synthesis were performed 
as described above. 2 μl of each cDNA reaction was used as template in a nested PCR 
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reaction specific for ORF73 spliced transcripts as described (1), and products of the reaction 
were separated on a 1.5% agarose gel. cDNA from S11 cells was used as a positive control, 
and cDNA generated from uninfected splenocytes was used as a negative control. 
 
Mice infection, R848 treatment, and limiting-dilution nested PCR. Mice were infected by 
injecting 105 pfu of MHV-68 i.p. in 100μl PBS. Daily treatment was done with 1mg/kg body 
weight R848 in 100μl PBS based on previous work (2), or PBS alone by i.p. injection for 19 
days. At 20 dpi, mice were sacrificed by inhalation of CO2, and splenocytes were isolated as 
described above. The frequency of MHV-68 genome-positive cells was determined by a 
previously published method (45). Nonlinear regression curve was fit using GraphPad Prism 
software (La Jolla, CA). Frequencies were calculated as the splenocyte number at which 
63.2% of reactions were positive based on Poisson distribution. 
 
TLR downregulation by RNA interference. S11 cells were transfected with psiRNA-h7SK 
plasmids expressing shRNA targeting tlr7, tlr9, or Luciferase gene, respectively, as well as 
green-fluorescent protein (GFP) and Zeocin resistance from a separate promoter (Invivogen, 
San Diego, CA). Transfection was performed using NEON® Transfection System 
(Invitrogen, Carlsbad, CA) according to the manufacturers instructions. Transfected cells 
were selected in complete RPMI containing 200 μg/ml Zeocin (Invivogen, San Diego, CA) 
and successful selection was confirmed by flow cytometry. 
 
Ex vivo MHV-68 reactivation assay. Mice were sacrificed by terminal anesthesia using a 
CO2 chamber. Whole spleens were harvested, transferred to ice-cold PBS and passed through 
a 70 μm nylon mesh cell strainer (BD Falcon, BD Biosciences, Chicago, IL). Erythrocytes 
were removed by ammonium chloride lysis solution (Stemcell Technologies, Grenoble, 
France). B-cells were isolated by negative selection using a murine B-cell isolation Kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Purified B-cells were counted and 
resuspended in a two-fold dilution series starting at 106 cells/ml. Dilutions were plated on 
monolayers of NIH3T12 murine fibroblasts in a 96-well plate, 100 μl/well and 12 wells per 
dilution. As a control, uninfected B-cells were plated in 12 wells at 105 cells per well. 9 days 
later, wells were inspected for cytopathic effect by microscopy and the frequency of 
reactivation was calculated based on Poisson distribution. 
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Statistical analysis. Data were statistically analyzed with the unpaired t-test using GraphPad 
Prism software (La Jolla, CA). P values below 0.05 were considered statistically significant. 
 
RESULTS 
Stimulation of endosomal TLR7 and TLR9 but not TLR3 causes nuclear accumulation 
of NFκB p65 in S11 cells 
To investigate the effects of TLR triggering on latent gamma-herpesvirus infection in vitro, 
we used the latently MHV-68-infected murine B-lymphocyte cell line S11. S11 was isolated 
from a lymphoma in a BALB/c mouse infected with MHV-68; each S11 cell harbors 
reactivation competent MHV-68 (47).  
First, we verified that S11 cells express signaling-competent TLR3, TLR7, and TLR9 
using reverse transcription PCR (Fig. 1A). To confirm activation of NFκB upon TLR 
triggering, we treated S11 cells with ligands to TLR3, TLR7, and TLR9 and NFκB inhibitor 
Bay 11-7082, respectively, and assessed subsequent nuclear accumulation of NFκB subunit 
p65 at different time points by Western blotting (Fig. 1B, PCNA loading controls see Fig. 
S1).  
Poly(I:C) did not lead to any accumulation of NFκB p65 in the nucleus. Conversely, 
R848 that triggers TLR7 and CpG ODN 1826 which triggers TLR9 lead to activation of 
NFκB. S11 cells treated with R848 or CpG ODN 1826 showed stronger nuclear accumulation 
of NFκB p65 compared to untreated cells for at least 24 h after treatment (Fig. 1B). By 
contrast, NFκB inhibitor Bay 11-7082 reduced nuclear NFκB p65 to minimal levels at 1.5 h 
after treatment (Fig. 1B).  
To verify signaling competence, we measured the induction of cytokine expression in 
response to TLR ligands by qPCR (Fig. 1C). TLR3 ligand Poly(I:C) robustly induced 
expression of IFN-β1 (Fig. 1C, left panel), most likely by activating Interferon regulatory 
factor 3 (IRF3) pathway (53) while R848 and CpG ODN 1826 did not. On the other hand, 
R848 and CpG ODN 1826 induced expression of the cytokines IL-6 (Fig. 1C, middle panel) 
and IL-10 (Fig. 1C, right panel) while Poly(I:C) did not. 
These results demonstrate that endosomal TLRs activate distinct signaling pathways 
resulting in differential induction of transcription factors in the S11 model cell line. While the 
stimulation of TLR7 and TLR9 leads to activation of NFκB and subsequent induction of IL-6 
and IL-10, stimulation of TLR3 does not activate NFκB but rather induces expression of IFN-
β, probably via IRF3 transcription factor. 
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Stimulation of TLR7 and TLR9 but not TLR3 suppresses both spontaneous and induced 
MHV-68 reactivation in S11 cells 
A fraction of S11 cells constantly undergoes spontaneous reactivation from latent MHV-68 
infection as evidenced by expression of ORF50, the initiator of lytic replication (52) as well 
as shedding of infectious MHV-68 particles to the supernatant. The frequency of reactivation 
of MHV-68 can be increased by treatment with 12-O-tetradecanoyl-13-phorbolacetate (TPA) 
(47). 
To monitor the impact of endosomal TLR triggering on MHV-68 reactivation, S11 
cells were treated with Poly(I:C), R848 and CpG ODN 1826, respectively, for 24 h before 
analyzing the mRNA expression levels of immediate-early lytic gene ORF50 (Fig. 2A, black 
bars), early lytic gene ORF21 and late lytic gene M7 (31) by qPCR as well as measuring 
infectious MHV-68 particles in the supernatant by plaque assay (Fig. 2A, white bars). 
Treatment with 25 µg/ml Poly(I:C) did not change the expression of ORF50 or the release of 
infectious particles. Treatment with 3 µM R848 or 0.5 µM CpG ODN 1826, however, 
decreased the levels of all lytic genes compared to the mock-treated control (Fig. S2), which 
was compatible with suppression of the entire MHV-68 lytic transcription program. 
Consequently, the titer of infectious MHV-68 in the supernatant decreased by about 50% 
compared to the mock-treated control. Addition of 10 ng/µl TPA to the culture medium for 24 
h increased the mRNA levels of ORF50 about 4-fold and MHV-68 particle production about 
2-fold compared to the control. When the cells were treated with R848 or CpG ODN 1826 2 h 
prior to adding TPA, the pro-lytic effect was abolished. Taken together, these results indicate 
that signaling by TLR7 and TLR9 suppresses both spontaneous as well as induced 
reactivation of the lytic cycle while TLR3 signaling has no effect. 
Next, we wanted to see whether the suppressive effect of TLR7 and TLR9 stimulation 
is dependent on their ability to activate NFκB. To this end, we treated S11 cells with 1 µM 
NFκB inhibitor Bay 11-7082 2 h prior to the stimulation with TLR ligands and analyzed lytic 
reactivation 24 h later (Fig. 2B). We found that pre-treatment with Bay 11-7082 completely 
abolished the suppressive effect of CpG ODN 1826 and partially abolished the effect of R848, 
indicating that the impact of TLR triggering on lytic replication is at least partially dependent 
on NFκB activation. In the absence of TLR stimulation, the treatment with Bay 11-7082 led 
to a slight increase in lytic reactivation compared to mock-treated control, in good agreement 
with earlier reports in which Bay 11-7082 provoked reactivation of the human gamma-
herpesviruses EBV and KSHV from latently infected B-cells in vitro (4, 17). 
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Stimulation of TLR7 in vivo leads to increased frequency of infected splenocytes after 
intraperitoneal injection of MHV-68 
Based on our in vitro data, and since NFκB activation was shown to be important for the 
establishment of latent MHV-68 infection in vivo (28), we hypothesized that TLR7-mediated 
activation of NFκB would support the establishment of MHV-68 latency in vivo in a similar 
fashion as shown for TLR9 (14).  
To test this hypothesis, we infected 10 C57BL/6 mice intraperitoneally (i.p.) with 
1x105 pfu MHV-68. We chose i.p. infection since this route seeds MHV-68 directly to the 
spleen without the need of amplification through lytic replication (49), therefore allowing the 
virus to reach the main site of latent infection directly. One day post inoculation (dpi) the 
mice were segregated into two groups and treated daily with either 1 mg/kg R848 in 100 μl of 
PBS or PBS alone (mock) i.p. for 19 days. Mice were sacrificed at 20 dpi, a time when lytic 
MHV-68 infection has been cleared from the spleen and predominantly latent infection can be 
expected (49). 
To investigate whether treatment with R848 following inoculation with MHV-68 
facilitates establishment of latent infection we isolated splenocytes from mice at 20 dpi and 
subjected them to analysis by limiting dilution nested PCR targeting MHV-68 gene v-cyclin 
(ORF72). We found that splenocytes from mice treated daily with R848 showed a 7-fold 
higher frequency of cells positive for MHV-68 genome than splenocytes from mice mock-
treated with PBS (1 in 100 vs. 1 in 750; Fig 3A).  
To confirm latent MHV-68 infection, we tested the splenocytes for expression of 
spliced variant of ORF73 (mLANA), a transcript associated with MHV-68 latency (1), by 
reverse transcription PCR (Fig. 3B). At 20 dpi, ORF73 spliced transcripts were detected in all 
samples from mice treated with R848 but inconsistently in samples from mock treated mice, 
reflecting the lower frequency of splenocytes harboring latent MHV-68. 
Thus, TLR7 triggering clearly promotes establishment of infection and the size of 
latent MHV-68 reservoir. 
 
Silencing of TLR9 but not TLR7 leads to decreased levels of nuclear NFκB and 
enhanced reactivation in S11 cells 
Latently MHV-68-infected S11 cells show a basal level of NFκB activity (Fig. 1B). Since 
nucleic-acid binding endosomal TLRs have been implicated in the sensing of various viral 
infections and TLR7 and TLR9 both have the ability to activate NFκB, we aimed at 
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investigating whether the basal activity of NFκB is mediated by TLR sensing of MHV-68 
infection. 
To assess the role of TLR7 and TLR9 in this context, S11 cells were transfected with 
plasmids expressing shRNA against TLR7, TLR9, or luciferase as control. Antibiotic 
selection yielded stable cell lines with >95% of the cells expressing the GFP cassette included 
in the vector containing the shRNA (Fig. S3). Stably transfected cells showed a reduction in 
TLR7 mRNA of 70% and a reduction of TLR9 mRNA of 55%, respectively, as measured by 
qPCR (Fig. 4A). S11 cell lines genetically complemented with shRNA against luciferase 
(shLuc) did not have any effect on TLR expression and served as control.  
Levels of NFκB p65 was similar in cells with reduced expression of TLR7 as in 
parental S11 cells as well as in the control cell line shLuc. In cells with reduced TLR9 
expression however, lower levels of nuclear NFκB p65 were detected.  We therefore 
hypothesize that latent MHV-68 infection causes a constant low-level activation of TLR9 but 
not TLR7 signaling pathway culminating in the nuclear translocation of NFκB p65, thereby 
contributing to a basal NFκB activation. 
Since in previous experiments a reduction in nuclear NFκB p65 by the inhibitor Bay 
11-7082 resulted in increased reactivation and viral production (Fig. 2B), we tested whether 
the stable cell lines silenced for TLR7 or TLR9 differed in their general propensity to 
spontaneous reactivation compared to the parental cell line. Quantification of lytic viral gene 
expression by real-time PCR and of infectious viral particle production by plaque assay 
revealed a 2-fold increase in expression of ORF50 (Fig. 4C, black bars) as well as a 2-fold 
increase in the concentration of viral particles in the supernatant (Fig. 4C, white bars) of cell 
lines silenced for TLR9 but not of cell lines silenced for TLR7 or of the control cells 
expressing shRNA against luciferase.  
These results suggest a contribution of continuous TLR9 signaling to basal NFκB 
activation levels and suppression of spontaneous reactivation. 
 
Lack of TLR9 does not impact early establishment of infection in vivo but favors 
reactivation of primary B-cells ex vivo  
Since activation of the TLR7 and TLR9 pathways support the establishment and maintenance 
of latent MHV-68 infection in splenocytes and since MHV-68 infection itself might promote 
latency via triggering TLR9, we hypothesized that lack of TLR9 would result in a reduced 
latent reservoir of MHV-68.  Thus, we infected i.p. wild-type (wt), tlr7-/- and tlr9-/-  mice (each 
of the genotypes n=15) with MHV-68; as performed, focusing on the de novo establishment 
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of infection in splenic B-cells, the consensus primary site of MHV-68 latency. None of the 
mice showed signs of distress or illness throughout the course of the experiment and all 
animals were sacrificed at 7 dpi. 
We did not find significant differences in the frequency of infected B-cells between 
any of the three groups (wt: 1 in 2,700; tlr7-/-: 1 in 3,300; tlr9-/-: 1 in 4,200) performing 
limiting-dilution nested PCR on purified B-cells (Fig 5A). We then assessed ex vivo 
reactivation of B-cells by limiting-dilution reactivation assay and found a higher frequency of 
reactivating tlr9-/- B-cells compared to wt or tlr7-/- (wt: 1 in 950,000; tlr7-/-: 1 in 1,000,000; 
tlr9-/-: 1 in 370,000). These findings are in line with both our in vitro results from silencing 
TLR7 or TLR9 in S11 cells as well as with the findings reported by Guggemoos et al. (18) 
who found higher titers of lytic MHV-68 in tlr9-/- mice than in wt mice after i.p. infection. 
Thus, it seems that impaired TLR9 signaling renders MHV-68-infected B-cells more likely to 
reactivate whereas impaired TLR7 signaling does not.  
 
DISCUSSION 
Activation of the innate immune system via TLRs largely impacts on gamma-herpesvirus 
latency and reactivation. We here studied the effect of endosomal TLR stimulation on latently 
infected cells in vitro and on the establishment of gamma-herpesvirus infection in vivo using 
the MHV-68 mouse model. We found that (i) signaling of TLR7 or TLR9 but not of TLR3 
inhibit both spontaneous and induced reactivation in the latently MHV-68-infected B-cell line 
S11 and that this effect is, at least partially, dependent on the induction of NFκB; (ii) 
stimulation of TLR7 during infection increases the number of latently infected splenocytes; 
(iii) downregulation of TLR9 but not of TLR7 reduces basal NFκB activity and increases 
spontaneous MHV-68 reactivation in latently infected cells; and (iv) while the lack of TLR7 
or TLR9 does not change the frequency of infected B-cells in vivo, MHV-68-infected B-cells 
from tlr9-/- mice show increased propensity to reactivate ex vivo. Our results unprecedentedly 
show that activation of NFκB via TLR7 signaling profoundly impacts the establishment and 
maintenance of latent MHV-68 infection, as is the case for TLR9 signaling. In absence of 
external ligands, constant activation of TLR9 caused by persistent MHV-68 infection might 
contribute to robust activation of NFκB, thus creating a favorable environment for latency. 
Our in vitro experiments using S11 cells as a model for established MHV-68 latency 
invariably showed that activation of the TLR9 pathway suppresses spontaneous as well as 
induced MHV-68 reactivation (Fig. 2A). It seems likely that this feature is shared by other 
gamma-herpesviruses, as previous studies in our lab demonstrated that stimulation by CpG 
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ODN similarly leads to a suppression of BZLF1 expression (29, 56), EBV’s master regulator 
lytic gene (46), in Burkitt’s lymphoma cells. Our finding that signaling via TLR7 suppresses 
MHV-68 reactivation is unprecedented. It seems plausible that TLR7 and TLR9 would have a 
comparable effect when stimulated, since they share a signaling pathway via the common 
adaptor molecule MyD88. Upon stimulation of either receptor we observed comparable 
activation of NFκB, albeit with slightly distinct kinetics (Fig. 1B). The facts that NFκB 
inhibitor counteracts the suppression by TLR ligands and in former studies NFκB was shown 
to suppress the lytic gene promoters of MHV-68 as well as the human gamma-herpesviruses 
EBV or KSHV (4, 22) support the hypothesis that downregulation of lytic MHV-68 upon 
TLR7 or TLR9 stimulation in S11 cells is due to activation of NFκB. Nevertheless, we cannot 
exclude that triggering of endosomal TLRs might activate cellular signaling pathways apart 
from NFκB that might impact on MHV-68 gene expression. In vitro data of Gargano et al. 
(14) showed that TLR3 or TLR9 triggering provoked lytic MHV-68 reactivation in the cell 
lines A20HE1 and A20HE2 while TLR7 triggering had no effect. The activation of NFκB 
was not tested. Thus, differences in endogenous levels of NFκB activation or TLR signaling 
competence between these cell lines might account for the divergent observations. 
Alternatively, the reason for the apparently contradictory observations may lie in the distinct 
origin of MHV-68 persistent infection. While S11 cells derive from a naturally MHV-68-
associated lymphoproliferation, A20HE1 and A20HE2 cell lines derive from murine 
lymphoma cells secondarily infected in vitro with a recombinant strain of MHV-68 (13). In a 
different study, increased reactivation of KSHV from primary effusion lymphoma cells was 
shown upon treatment with ligands to TLR7/8 (16). The critical signaling pathway in these 
cells was shown to be dependent on IRF7, however, further demonstrating that the impact of 
TLR signaling on gamma-herpesvirus reactivation may depend on cellular context. 
In vivo, recurrent activation of TLR7 signaling by treatment with R848 following de 
novo infection of wt mice led to a higher frequency of MHV-68 infected splenocytes 
compared to mock treatment (Fig. 3A). This observation is comparable with the findings of 
both Gargano et al. (14) as well as Ptaschinski et al. (34) who reported increased frequency of 
infected splenocytes in vivo upon stimulation of TLR9 by administration of CpG ODN. A 
higher frequency of cells positive for MHV-68 genome indicates an increase in the pool of 
latently MHV-68-infected cells and this is supported by the detection of MHV-68 latency-
associated mLANA transcripts in our experiments (Fig. 3B). Failure to detect mLANA 
transcripts in two samples from untreated controls reflects the limit of detection of the nested 
PCR rather than absent infection, since splenocytes from all mice were positive for MHV-68 
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genome (Fig. 3A) but only 5-10% of latently infected cells are expected to express mLANA 
(1). Based on our observations in vitro, we hypothesize that both TLR7 and TLR9-induced 
activation of NFκB promotes maintenance and expansion of the latently infected B-cell pool. 
Notably, stimulation with TLR ligands has been shown to induce proliferation of murine B-
cells (19) and is known to synergize with EBV in driving proliferation of EBV-infected 
human B-cells (21), which could explain elevated frequencies of infected cells without the 
need for lytic replication. Our hypothesis is supported by the absence of late lytic MHV-68 
gene expression reported by Ptaschinski et al. (34). The importance of functional NFκB for 
the establishment of MHV-68 latency in vivo has been elegantly demonstrated by Krug et al. 
(28) who reported severe impairment in establishment of splenic latency by a recombinant 
strain of MHV-68 that expresses a constitutively active form of the NFκB inhibitor IκBαM. 
Furthermore, NFκB signaling has been shown to be an important factor for the survival of 
lymphoma cells latently infected with KSHV (26) and EBV-transformed B-cells in vitro (5). 
We observed a constant activation of the NFκB pathway in the model cell line S11 as 
evidenced by high basal levels of NFκB subunit p65 in the nucleus (Fig. 4B), which drives 
survival and proliferation (24). NFκB levels in the nucleus were reduced by stable 
downregulation of TLR9 but not of TLR7 expression by RNA interference which 
consequently led to an increased rate of spontaneous reactivation (Fig. 4C), implying a 
constant stimulation of TLR9 in infected S11 cells. Spontaneous reactivation of MHV-68 is 
more frequent in S11 cells than in MHV-68-infected B cells in vivo and therefore the effect of 
TLR9-mediated NFκB activation might be rather high in comparison to latent infection in 
vivo. Nevertheless, it has been shown by various groups that TLR9 is triggered upon infection 
by herpesviruses (36, 40), including members of the gamma-herpesvirus family EBV (12) and 
KSHV (50). Suppression of lytic viral genes mediated by NFκB induction upon infection 
might serve as a negative feed-back loop with the potential to limit productive replication and 
initiate the latent state during acute infection in vivo. Additionally, such a mechanism could 
function as a homeostatic sensor to locally limit reactivation from latency. 
 Unlike TLR9, TLR7 does not contribute to NFκB activation in S11 cells in the 
absence of external stimulation. The main function attributed to TLR7 is the sensing of RNA 
viruses such as vesicular stomatitis virus and influenza (30). Only in one case is TLR7 
reported to recognize the herpesvirus murine cytomegalovirus (57), a study, however, done in 
the context of plasmacytoid dendritic cells rather than B-cells. 
In the context of de novo infection in vivo, our experiments with mice lacking either 
TLR7 or TLR9 did not show a significant difference in the frequency of infected splenic B-
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cells at an early time following i.p. infection. It is possible that during prolonged infection, 
deficiencies in TLR signaling impact on the number of latently infected cells since a ten-fold 
decrease in infected splenocytes was reported in myd88-/- mice at 42dpi (15). While the 
numbers of infected B-cells in our experiments were comparable, B-cells from tlr9-/- mice 
showed a higher propensity to reactivate ex vivo while the tlr7-/- B-cells did not, in agreement 
with the results obtained with S11 cells. 
Taken together, our results point towards an important role of TLR7- and TLR9-
mediated activation of NFκB in promoting persistent infection of MHV-68 in B-cells and 
show that TLR9 triggering by persistent MHV-68 infection might contribute to maintaining 
NFκB activation during latency. Considering that we did not see a significant difference in the 
frequency of infected B-cells in vivo, it is conceivable that there are other systems in place 
contributing to NFκB activation, for example the retinoic-acid-inducible-gene (RIG)-I system 
that synergizes with TLR9 to induce the immune response against herpes simplex virus (36). 
Other gamma-herpesviruses use activation of NFκB in the host cell for benefit as evidenced 
by EBV’s binding to the cellular receptor CD21, which induces NFκB that in turn mediates 
activation of the viral latent gene promoter (42) or the sustained moderate activation of NFκB 
reported upon infection of endothelial cells by KSHV that regulates viral gene expression(38). 
Taken together, the latency-promoting effect of endosomal TLR-mediated NFκB 
activation reported here suggests a possible mechanism for the role of co-infections that are 
implicated in the pathogenesis of certain gamma-herpesvirus-associated malignancies. 
Indeed, with respect to EBV-associated malignancies, the parasite Plasmodium falciparum 
that causes malaria and is epidemiologically associated with endemic Burkitt’s lymphoma 
was reported to directly stimulate TLR9 (7, 33). We showed that P. falciparum hemozoin 
suppresses lytic reactivation of EBV in Burkitt’s lymphoma cells Akata (56), further 
underscoring a possible mechanistic link between malaria infection and the incidence of 
EBV-positive Burkitt’s lymphoma. The situation in KSHV-associated primary effusion 
lymphoma, however, may be distinct as suggested by the lytic reactivation of KSHV 
following triggering of TLR7/8 (16). Nevertheless, our results are important in the light of 
TLR ligands being increasingly used as adjuvants in the treatment of infectious diseases, 
cancer or autoimmunity because of their potential to promote gamma-herpesvirus latency that 
may contribute to tumorigenesis. 
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Abstract 
Endemic Burkitt's Lymphoma is the most common pediatric cancer in equatorial africa. It is 
associated with gamma-herpesvirus Epstein-Barr virus and only occurs in regions where 
transmission of the malaria parasite Plasmodium falciparum is holoendemic, thus it is 
suspected to be a polymicrobial disease. Eventhough association with both EBV and malaria 
are established, the exact mechanism how chronic P.falciparum infection impacts on 
normally asymptomatic EBV and promotes incidence of EBV-positive cancer is unknown. 
Here we show that hemozoin, a waste product of parasite metabolism extracted from 
P.falciparum cultures in vitro, suppresses lytic reactivation from latency in both EBV-
infected Burkitt's Lymphoma cells as well as mouse lymphoma cells infected with murine 
gamma-herpesvirus 68. Suppression of viral reactivation was only seen when cells were 
stimulated with natural hemozoin extract but not with synthetic analogue β-hematin. 
Suppression of lytic reactivation promotes latency and has been shown to increase the 
frequency of infected cells in vivo. We hypothesize that chronic malaria contributes to the 
incidence of eBL by suppressing EBV reactivation via constant shedding of hemozoin to the 
bloodstream and therefore increasing the pool of latently infected B-cells. 
Manuscripts 
78	  
 
Introduction 
Endemic Burkitt’s Lymphoma (eBL) is the most common cancer in infants of equatorial 
Africa. The Irish surgeon Denis Burkitt first described this particularly fast growing B-cell 
malignancy in children in Uganda [1]. He established that eBL was restricted to climatic 
zones where the malaria parasite Plasmodium falciparum is holoendemic and concluded that 
eBL is associated with malaria [2,3]. Meanwhile, British Pathologist Anthony Epstein and his 
co-workers Bert Achong and Yvonne Barr identified virus particles resembling herpesviruses 
in cultured cells of a specimen of eBL from Uganda by electron microscopy [4]. The newly 
discovered virus was subsequently named Epstein-Barr virus (EBV) and turned out to be 
present in almost 100% of eBLs as well as in other cancers such as nasal carcinoma [5]. 
Further epidemiological evidence strongly suggested a causal relationship between EBV and 
eBL [6], even before the oncogenic potential of EBV, i.e., its ability to transform B-cells in 
vitro was demonstrated [7]. 
Both continuous exposure to the malaria agent Plasmodium falciparum and persistent 
infection with EBV have been identified as necessary co-factors for the development of eBL. 
Therefore, it seems likely that eBL should be considered a polymicrobial disease where 
chronic infection with Plasmodium falciparum is a prerequisite to create an environment in 
which an usually asymptomatic EBV persistence may turn into eBL. Yet, the tumorigenic 
pathogenetic mechanism of interaction between the virus and the parasite is unclear. 
Several clinical studies have elaborated evidence for the impact of malaria on 
persistent EBV infection. Lam and colleagues [8] reported a 5-fold increase in the frequency 
of EBV-positive B-cells in the peripheral blood of children during acute malaria. These 
findings were confirmed by reports of increased EBV DNA levels in whole blood samples of 
pediatric patients from a region where malaria transmission is high compared to patients from 
a region where transmission is low [9], as well as 10-fold increase of EBV DNA load in 
peripheral blood mononuclear cells in children with malaria [10]. Thus, infection with 
Plasmodium falciparum seems to increase the number of latently EBV-infected B-cells and 
might therefore promote the risk for eBL. 
Studies in our lab have shown that constant stimulation of the innate immune system 
via systemic administration of a synthetic ligand to Toll-like receptor (TLR)7 leads to a 
similar infection pattern with an increased frequency of latently infected B-cells in an in vivo 
infection model using murine gamma-herpesvirus 68 (MHV-68) (Haas, manuscript 
submitted). These results are in line with earlier studies reporting increased frequencies of 
infected splenocytes in MHV-68-infected mice following stimulation of TLR9 [11], which 
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shares a signaling pathway with TLR7. We further determined that stimulation of TLR7 and 
TLR9 suppresses MHV-68 reactivation in vitro. Therefore, we hypothesized that constant 
stimulation of TLR7 or TLR9 leads to increased frequencies of latently MHV-68-infected B-
cells in vivo due to the reactivation-suppressing effect, in turn promoting latency over lytic 
replication and thus the survival of the infected host cell. Additionally, it is known that 
stimulation of TLR signalling pathways induces proliferation in B-cells [12], an effect likely 
contributing to the expansion of the reservoir of latently infected cells. 
We found a similar reactivation-suppressing effect of TLR9 signalling in EBV-
infected Burkitt's Lymphoma cells in vitro [13]. It is conceivable that continuous stimulation 
of TLR9 would expand the pool of infected B-cells in vivo in a similar fashion as seen in the 
mouse model. This raises the question whether the observed expansion of latently EBV-
infected B-cells in the peripheral blood of patients chronically exposed to Plasmodium 
falciparum infection might be due to continuous stimulation of endosomal TLRs. 
There is solid evidence that Plasmodium falciparum interacts with members of the 
TLR family. Plasmodium schizont extracts were demonstrated to stimulate dendritic cells via 
a TLR9-dependent pathway [14] and the Plasmodium waste product hemozoin was identified 
as a natural ligand for TLR9 [15]. Hemozoin is a crystalline compound formed in parasitized 
red blood cells in order to detoxify free heme that accumulates as the parasite digests 
hemoglobin [16]. Upon rupture of the red blood cell, hemozoin is released into the blood 
stream and potentially phagocytosed by immune cells. This makes hemozoin an interesting 
candidate for TLR9 stimulation in B-cells. Nevertheless, it is not undisputed whether 
hemozoin itself or associated parasite products are responsible for TLR stimulation. While 
several studies [15,17,18] claim that synthetic pure hemozoin crystals bind to and stimulate 
TLR9, findings by another group argue that it is not the hemozoin itself but rather hemozoin-
associated Plasmodium DNA that elicits TLR9 responses [19]. 
Considering above commented literature, we hypothesize that recurring infection with 
Plasmodium falciparum contributes to eBL by promoting both proliferation and survival of 
latently EBV-infected B-cells via constant activation of TLR signalling, thus suppressing viral 
reactivation. 
To test this hypothesis, we investigated whether Plasmodium-derived hemozoin or 
chemically synthesized hemozoin analog (β-hematin) acts as natural TLR9 ligand and 
reproduces the suppressive effect on gamma-herpesvirus reactivation that we found for 
canonical ligands to TLR9 such as CpG oligodenucleotides. 
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Results 
Hemozoin isolated from P. falciparum cultures suppresses induced and spontaneous 
reactivation of gamma-herpesviruses 
As we have shown previously, stimulation of gamma-herpesvirus infected B-cells with 
ligands to TLR9 can suppress viral reactivation by downregulating lytic viral gene expression. 
Since the malaria pigment hemozoin was reported to stimulate TLR9, we asked whether 
natural hemozoin from P. falciparum cultures was able to suppress gamma-herpesvirus lytic 
replication in vitro.  
We therefore stimulated the latently EBV-infected BL cell line Akata with increasing 
concentrations of hemozoin or the synthetic TLR9 ligand CpG as a positive control and 
subsequently induced reactivation by crosslinking the B-cell-receptor with anti-IgG 
antibodies as described before [20]. Six hours after cross-linking the BCR, we measured the 
expression level of EBV’s master lytic regulator gene BZLF1 [21] by quantitative polymerase 
chain reaction (qPCR) (Fig.1A). In untreated Akata cells, the expression of BZLF1 was found 
to be below detection level, and the addition of TLR9 ligand CpG did not change that. 
Treatment of Akata cells with anti-IgG antibody resulted in a strong increase of BZLF1 
expression, indicating the induction of lytic EBV replication. Pretreatment with CpG 
diminished the induction of BZLF1 expression to about 20%. Interestingly, at higher 
concentrations, pretreatment with natural hemozoin hindered induction of lytic EBV gene 
expression in a dose-dependent manner. 
Next, we tested the impact of hemozoin on another gamma-herpesvirus, the murine 
pathogen murine herpesvirus 68 (MHV-68). Latently MHV-68-infected S11 cells were 
treated with increasing concentrations of hemozoin or mouse-optimized CpG ODN 1826 as a 
positive control. 24 hours after stimulation, expression of the master lytic regulator gene of 
MHV-68, ORF50, was measured by qPCR (Fig.1B). Since spontaneous reactivation events 
are much more frequent in this cell line than in Akata, induction of the lytic cycle was not 
necessary for these experiments to readily detect expression of ORF50. Similarly to the 
previous results in Akata cells, treatment with hemozoin decreased the expression of ORF50 
in a dose-dependent manner. 
To check whether hemozoin blocks induced gamma-herpesvirus reactivation 
analogous to the experiments in Akata, we incubated MHV-68-infected murine B-cell line 
A20HE1 with natural hemozoin and subsequently tried to reactivate MHV-68 by addition of 
Tetradecanoylphorbol acetate (TPA), an activator of gamma-herpesvirus lytic replication 
[22]. As expected, addition of TPA alone increased ORF50 expression 8-fold (Fig.1C). 
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However, if the cells were preincubated with the natural hemozoin extract, the induction of 
lytic MHV-68 gene expression was substantially weakened. 
These experiments showed that a hemozoin extract from P. falciparum cultures is able to 
suppress both spontaneous as well as induced reactivation of lytic replication in two species 
of gamma-herpesviruses. 
 
Synthetic hemozoin can be polymerized from hemin and is indistinguishable from the natural 
hemozoin by infrared spectroscopy 
Our first series of experiments was conducted with hemozoin extracted from P. falciparum 
cultures by using its magnetic properties. Since there are contradictory reports whether the 
hemozoin itself or rather contamination by parasite DNA or other products are the stimulating 
agent [19], we next asked if a synthetic hemozoin-like crystal can reproduce the repressive 
effect on gamma-herpesvirus replication that we observed with both hemozoin and CpG.  
The synthetic hemozoin, called β-hematin, was polymerized from porcine hemin by a 
method adapted from Jaramillo et al [17]. The resulting product was analyzed by infrared 
spectroscopy (Fig.2). The spectrum showed three major peaks characteristic for β-hematin at 
1712 cm-1, 1662 cm-1 and 1210 cm-1. Comparison with IR-spectra of synthetic β-hematin 
synthesized by other groups (Fig.2, small panel) or natural hemozoin confirmed composition 
and strucure of the compound (Fig. 2). 
 
Synthetic hemozoin compound does not suppress gamma-herpesvirus lytic reactivation 
To test whether the crystalline structure itself or possible contaminants in the natural 
hemozoin extract are reponsible for the effect observed in Fig.1, we repeated the experiments 
with newly synthesized hemozoin. First, we treated Akata cells with increasing concentrations 
of synthetic hemozoin (sHz) or TLR9 ligand CpG and after 2h induced lytic replication by 
IgG crosslinking. While CpG treatment reduced BZLF1 expression to the same extent as 
before, no reduction in lytic EBV gene expression was observed after preincubation with sHz 
(Fig.3A). In the murine cell line S11 harbouring MHV-68, we also did not observe changes in 
lytic MHV-68 gene expression upon stimulation of the cells with sHz (Fig.3B). 
 
Addition of P.falciparum DNA does not restore the effect of synthetic Hz on MHV-68 lytic 
replication 
Parroche et al. [19] investigated the immunogenicity of both natural hemozoin and its 
counterpart β-hematin and came to the conclusion that β-hematin was immunologically inert. 
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They further reported that the stimulatory effect of natural hemozoin is caused by 
Plasmodium DNA bound to its surface. We wanted to test whether the addition of 
Plasmodium DNA to the synthetic hemozoin might restore the effect of natural hemozoin on 
MHV-68 gene expression. We mixed sHz with Plasmodium DNA at varying concentrations 
and used the mixtures to stimulate S11 cells (Fig.4). sHz or Plasmodium DNA alone did not 
show any effect on ORF50 expression and neither did the combinations of the two. 
 
Discussion 
Hemozoin accumulates in parasitized red blood cells during P. falciparum infection, is 
subsequently released into the bloodstream, and has been claimed to be a ligand for TLR9. 
There is a controversy whether synthetically produced hemozoin itself binds to TLR9 or if 
parasite DNA bound to the crystal is responsible for the observed activation of TLR signaling. 
This is noteworthy since stimulation of TLR9 has a suppressive effect on gamma-herpesvirus 
lytic gene expression in vitro and leads to an increase in latently infected cells in vivo, similar 
to clinical observations in chronically malaria-infected patients. Therefore, we assessed the 
ability of natural hemozoin from P. falciparum cultures as well as synthetic β-hematin to 
suppress gamma-herpesviral lytic gene expression in vitro. We found that i) hemozoin 
extracts from Plasmodium culture downregulate the expression of lytic genes of two species 
of gamma-herpesviruses in a dose-dependent manner; ii) the synthetic hemozoin analogue β-
hematin does not change the expression of gamma-herpesvirus lytic genes; and iii) the 
addition of Plasmodium DNA to the β-hematin preparation did not restore the reactivation-
suppressing activity of hemozoin. 
In Burkitt's lymphoma cells Akata that are latently infected with EBV, increasing 
concentrations of natural hemozoin led to a reduction in viral lytic gene expression after 
cross-linking of the B-cell receptor. The observed suppression was not as strong as with the 
synthetic ligand CpG, but nevertheless significant at higher concentrations (Fig.1A). In S11 
cells infected with MHV-68 we showed a suppression of spontaneous lytic gene expression at 
a level close to that observed after treatment with CpG (Fig.1B). These results provide 
evidence for the ability of crude hemozoin extract to suppress reactivation in two gamma-
herpesvirus species reminiscent of the effect of TLR9 stimulation. Hemozoin was shown 
before to stimulate dendritic cells in a TLR9- and MyD88-dependent fashion [14,15]. Thus, it 
is reasonable to assume that the reactivation-suppressing effect stems from activation of 
TLR9 signaling. However, from our data we cannot exclude that other immune receptors are 
involved in this phenomenon as the crude hemozoin preparation might contain other 
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stimulatory agents such glycosylphosphatidylinositol (GPI) which was shown to activate 
TLR2 signaling [23] as well as Plasmodium-derived hypoxanthine/xanthine which is 
degraded to uric acid after red blood cell rupture and activates endosomal receptors such as 
NALP3 inflammasome [24]. 
To exclude stimulatory effects of unknown contaminants in our hemozoin preparation, 
we synthesized β-hematin from HPLC-purified hemin and confirmed the composition and 
structure by infrared spectroscopy. When we stimulated herpesvirus-infected cells with β-
hematin, we did not observe any change in lytic viral gene expression. This is in line with the 
results of Parroche et al. who found β-hematin to be immunologically inert and identified 
Plasmodium DNA associated with natural hemozoin as the active ligand for TLR9 [19]. On 
the other hand, there are several reports where β-hematin was found to activate TLR9 
signaling in dendritic cells and macrophages [17,18] and binding studies demonstrating the 
binding of β-hematin to TLR9 by circular dicroism spectrum analysis [25]. A potential 
explanation for this apparent contradiction was offered by Jaramillo et al. who found that the 
size of the β-hematin crystals varied greatly depending on the source of hemin and the 
method employed in synthesis and showed that the immunogenicity of the product is largely 
dependent on the size distribution of the particles. Since the β-hematin crystals are 
indistinguishable in their infrared spectrum irrespectable of size, we were not able to further 
determine the precise morphology of our crystals. 
According to Parroche et al. hemozoin acts as a vehicle for plasmodial DNA and 
facilitates the uptake into endsomes and presentation to TLR9. However, when we mixed β-
hematin with varying amounts of Plasmodium DNA, we were not able to reproduce the 
reactivation-suppressing effect of the natural hemozoin extract. However, as we did not 
control for the attachment of DNA to the β-hematin or the efficient uptake into cellular 
endosomes, we cannot conclusively state that such a process would not result in the 
stimulation of TLR9 and therefore suppress gamma-herpesvirus reactivation. 
Taken together, our results show that natural hemozoin extracted from P. falciparum 
culture leads to a reduction in gamma-herpesvirus lytic gene expression in vitro that is likely 
mediated by TLR9 signaling. In a mouse model, we showed before that constant stimulation 
of TLRs during persistent gamma-herpesvirus infection in vivo increases the number of 
latently infected B-cells in a similar fashion as seen for latent EBV infection in patients from 
regions with holoendemic malaria. It is therefore conceivable that the constant immune 
activation caused by malaria is an important factor in the etiology of eBls and that hemozoin 
is a possible mediator. However, we have to consider that constant immune stimulation is 
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probably not the only reason for a persistent EBV infection to develop into eBL. Another 
important factor might be that P. falciparum interferes with the host immune system and 
therefore weakens immune control of latent EBV infection. Several studies have shown that 
malaria leads to an impairement of EBV-specific CD8+ T-cell responses [26-29], eventhough 
the exact mechanism is unclear. Furthermore, P. falciparum erythrocyte membrane protein 1 
(PfEMP1) expressed on infected erythrocytes was reported to interfere with dendritic cell 
maturation, therefore hampering induction of an efficient cellular immune response [30]. 
 
Material and Methods 
Cell culture. Human Burkitt's Lymphoma cell line Akata (courtesy of Dr. A. Bell, 
Birmingham, UK) and MHV-68-infected murine B-cell line S11 (courtesy of Prof. Ren Sun, 
Los Angeles, CA) were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FCS), 1% penicillin-streptomycin and 2mM L-glutamine; (all 
reagents from Invitrogen, Basel, Switzerland) at 37°C and 5% CO2 humidified atmosphere. 
 
Natural hemozoin extract. Natural hemozoin extract was prepared as described by Parroche 
et al [19]. Erythrocytic stages of P. falciparum laboratory strain 3D7 were washed in PBS and 
resuspended at a hematocrit of ≈ 2%. RBC suspension was loaded onto an LS column 
(Miltenyi Biotec, Bergisch Gladbach, Germany) and placed in the MACS separator. The 
magnetic field allowed the hemozoin to be retained due to its magnetic properties, while the 
rest of the culture flowed through. The column was washed with PBS, removed from the 
magnetic field, and the hemozoin was eluted and quantified. 
 
Hemozoin quantitation. To quantify natural hemozoin extract, total heme content was 
determined as described before [31]. Hemozoin was depolymerized for 2 hours at room 
temperature in 20mM NaOH and 2% SDS. OD was read at 400nm using NanoDrop ND-1000 
Spectrophotometer (Witec AG, Luzern, Switzerland). 25μg of hemozoin or β-hematin 
contains 26-29 nmol of heme. 
 
Reverse transcription and quantitative PCR. Total RNA was extracted from cells using 
RNeasy Mini Kit (Qiagen, Hombrechtikon, Switzerland) and contaminating DNA was 
removed by DNAse treatment (DNA-free Ambion; Applied Biosystems, Rotkreuz, 
Switzerland). cDNA was synthesized using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Amplification of synthesized cDNA was performed using TaqMan® 
Manuscripts 
85	  
Gene Expression Master Mix (Applied Biosystems). For EBV lytic gene BZLF1 the following 
primers and probe were used: BZLF1_forward 5'-CACGACGTACAAGGAAAC-3'; 
BZLF1_reverse 5'-CGCTTTATTTCTAGTTCAGAATCGC-3'; BZLF1_probe 5'-FAM-
CAGCCAGAATCGCTGGAGGAA-BHQ-1-3'. For MHV-68 lytic gene ORF50 the following 
primers and probe were used: ORF50_forward 5’-CCAACGTGTTCCCAGAAC-3’; ORF50-
reverse 5’-CGATGAACGCGTCCTCAG-3’; ORF50_probe 5'-FAM-
TACTCAGGAAGCGTGTCCCGGATCA-BHQ-1. All reactions were run on ABI 7900HT 
Fast Real-Time PCR System (Applied Biosystems, Rotkreuz, Switzerland). Amplification of 
gapdh mRNA was used for normalization within each sample. 
 
Synthesis of β-hematin. β-hematin was produced by the aqueous acid-catalyzed method as 
proposed by Jaramillo et al [17]. 500mg of HPLC-purified hemin (Sigma-Aldrich, Buchs, 
Switzerland) was dissolved in 100ml degassed 0.1M NaOH under gentle stirring. Propionic 
acid was added dropwise until pH reached 4. The mixture was heated in a waterbath at 70°C 
for 18 hours, cooled down and then filtered. The product was scratched from the filter and 
washed in 100ml 0.1M NaHCO3 for 3 hours. The filtrate was then washed 3 times 
alternatingly in MilliQ H2O and Methanol before being dried over night in a vaccuum oven. 
The resulting product was analyzed in a infrared spectrometer. 
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